Thermo Fisher Scientific (TMO) 10-Q1 Aug 142014 Q2 Quarterly reportFinancial data

Company Profile

Document_and_Entity_Informatio

Document and Entity Information	6 Months Ended
Document and Entity Information	Jun. 28, 2014
Document and Entity Information [Abstract]	'
Entity Registrant Name	'Thermo Fisher Scientific Inc.
Entity Central Index Key	'0000097745
Document Type	'10-Q
Document Period End Date	28-Jun-14
Amendment Flag	'false
Current Fiscal Year End Date	'--12-31
Document Fiscal Year Focus	'2014
Document Fiscal Period Focus	'Q2
Entity Well-known Seasoned Issuer	'Yes
Entity Voluntary Filers	'No
Entity Current Reporting Status	'Yes
Entity Filer Category	'Large Accelerated Filer
Entity Common Stock, Shares Outstanding	399,354,992

Consolidated_Balance_Sheet_Una

Consolidated Balance Sheet (Unaudited) (USD $)	Jun. 28, 2014	Dec. 31, 2013
In Millions, unless otherwise specified	Jun. 28, 2014	Dec. 31, 2013
Current Assets:	'	'
Cash and cash equivalents	$584.90	$5,826
Short-term investments	21	4.5
Accounts receivable, less allowances of $84.6 and $54.1	2,660.10	1,942.30
Inventories	1,933.80	1,494.50
Deferred tax assets	237.5	192.5
Other current assets	507.1	420.9
Total current assets	5,944.40	9,880.70
Property, Plant and Equipment, at Cost, Net	2,472	1,767.40
Acquisition-related Intangible Assets, Net	15,621.60	7,071.30
Other Assets	836.1	640.7
Goodwill	19,439.30	12,503.30
Total Assets	44,313.40	31,863.40
Current Liabilities:	'	'
Short-term obligations and current maturities of long-term obligations	3,075.10	987.7
Accounts payable	849.9	691.5
Accrued payroll and employee benefits	535.8	432
Accrued income taxes	293.4	0
Deferred revenue	342.5	198.9
Other accrued expenses	1,138.90	815.9
Total current liabilities	6,235.60	3,126
Deferred Income Taxes	3,788.30	1,609.90
Other Long-term Liabilities	1,128.90	771.8
Long-term Obligations	12,502	9,499.60
Shareholders' Equity:	'	'
Preferred stock, $100 par value, 50,000 shares authorized; none issued	'	'
Common stock, $1 par value, 1,200,000,000 shares authorized; 407,241,027 and 369,598,265 shares issued	407.2	369.6
Capital in excess of par value	11,351.60	8,222.60
Retained earnings	9,454.60	8,753.30
Treasury stock at cost, 7,886,035 and 7,636,887 shares	-443.1	-412.2
Accumulated other comprehensive items	-111.7	-77.2
Total shareholders' equity	20,658.60	16,856.10
Total Liabilities & Shareholders' Equity	$44,313.40	$31,863.40

Consolidated_Balance_Sheet_Una1

Consolidated Balance Sheet (Unaudited) (Parenthetical) (USD $)	Jun. 28, 2014	Dec. 31, 2013
In Millions, except Share data, unless otherwise specified	Jun. 28, 2014	Dec. 31, 2013
Statement of Financial Position [Abstract]	'	'
Accounts Receivable Allowances	$84.60	$54.10
Preferred Stock, $100 Par Value - Par Value (in dollars per share)	$100	$100
Preferred Stock, $100 Par Value - Shares Authorized (in shares)	50,000	50,000
Preferred Stock, $100 Par Value - Shares Issued (in shares)	0	0
Common Stock, $1 Par Value - Par Value (in dollars per share)	$1	$1
Common Stock, $1 Par Value - Shares Authorized (in shares)	1,200,000,000	1,200,000,000
Common Stock, $1 Par Value - Shares Issued (in shares)	407,241,027	369,598,265
Treasury Stock at Cost (in shares)	7,886,035	7,636,887

Consolidated_Statement_of_Inco

Consolidated Statement of Income (Unaudited) (USD $)	3 Months Ended		6 Months Ended
In Millions, except Per Share data, unless otherwise specified	Jun. 28, 2014	Jun. 29, 2013	Jun. 28, 2014	Jun. 29, 2013
Revenues	'	'	'	'
Product revenues	$3,778	$2,786.80	$7,153.40	$5,510.30
Service revenues	543.9	453.3	1,072	921.3
Total revenues	4,321.90	3,240.10	8,225.40	6,431.60
Costs and Operating Expenses:	'	'	'	'
Cost of product revenues	2,112.90	1,572.50	4,046.20	3,105.60
Cost of service revenues	362.5	304.4	712.7	626.5
Selling, general and administrative expenses	1,253.80	869.6	2,430.80	1,699.10
Research and development expenses	183.7	96.7	333.4	194.9
Restructuring and other costs (income), net	60.9	21.5	-521.3	43
Total costs and operating expenses	3,973.80	2,864.70	7,001.80	5,669.10
Operating Income	348.1	375.4	1,223.60	762.5
Other Expense, Net	-111.6	-95.4	-212.7	-139.6
Income from Continuing Operations Before Income Taxes	236.5	280	1,010.90	622.9
Income Tax Benefit (Provision)	42	-2.4	-189.3	-4.5
Income from Continuing Operations	278.5	277.6	821.6	618.4
Loss from Discontinued Operations (net of income tax benefit of $0.1 and $0.3)	0	-0.2	0	-0.6
Loss on Disposal of Discontinued Operations, Net (net of income tax benefit of $2.8)	0	0	0	-4.2
Net Income	$278.50	$277.40	$821.60	$613.60
Earnings per Share from Continuing Operations	'	'	'	'
Basic (in dollars per share)	$0.70	$0.77	$2.07	$1.72
Diluted (in dollars per share)	$0.69	$0.76	$2.05	$1.71
Earnings per Share	'	'	'	'
Basic (in dollars per share)	$0.70	$0.77	$2.07	$1.71
Diluted (in dollars per share)	$0.69	$0.76	$2.05	$1.69
Weighted Average Shares	'	'	'	'
Basic (in millions of shares)	399.4	360	396.3	359
Diluted (in millions of shares)	403.1	363.5	400.7	362.6
Cash Dividends Declared per Common Share (in dollars per share)	$0.15	$0.15	$0.30	$0.30

Consolidated_Statement_of_Inco1

Consolidated Statement of Income (Unaudited) (Parenthetical) (USD $)	3 Months Ended	6 Months Ended
In Millions, unless otherwise specified	Jun. 29, 2013	Jun. 29, 2013
Income Statement [Abstract]	'	'
Provision for (Benefit from) Income Taxes on Income (Loss) from Discontinued Operations	($0.10)	($0.30)
Provision for (Benefit From) Income Taxes on Gain (Loss) on Disposal of Discontinued Operations	'	($2.80)

Consolidated_Statement_of_Comp

Consolidated Statement of Comprehensive Income (Unaudited) (USD $)	3 Months Ended		6 Months Ended
In Millions, unless otherwise specified	Jun. 28, 2014	Jun. 29, 2013	Jun. 28, 2014	Jun. 29, 2013
Comprehensive Income	'	'	'	'
Net income	$278.50	$277.40	$821.60	$613.60
Other Comprehensive Items:	'	'	'	'
Currency translation adjustment	-50.7	-135.7	-36.4	-315
Unrealized gains on available-for-sale investments:	'	'	'	'
Unrealized holding gains (losses) arising during the period (net of tax provision (benefit) of $0.1, ($0.1), $0.1 and $0.3)	1.8	-0.1	1.8	1.1
Reclassification adjustment for gains included in net income (net of tax provision of $0.0, $0.0 and $2.5)	-1.4	0	-1.4	-8
Unrealized gains and losses on hedging instruments:	'	'	'	'
Unrealized gain on hedging instruments (net of tax provision of $4.1 and $4.1)	0	6.7	0	6.7
Reclassification adjustment for losses included in net income (net of tax benefit of $0.5, $0.5, $0.9 and $1.0)	0.8	0.8	1.5	1.6
Pension and other postretirement benefit liability adjustment:	'	'	'	'
Pension and other postretirement benefit liability adjustments arising during the period (net of tax (benefit) provision of ($0.3), ($0.1), ($0.9) and $1.5)	-0.7	-0.3	-2.6	4.2
Amortization of net loss and prior service benefit included in net periodic pension cost (net of tax benefit of $0.6, $0.9, $1.2 and $1.8)	1.3	1.9	2.6	3.8
Total other comprehensive items	-48.9	-126.7	-34.5	-305.6
Comprehensive Income	$229.60	$150.70	$787.10	$308

Consolidated_Statement_of_Comp1

Consolidated Statement of Comprehensive Income (Unaudited) (Parenthetical) (USD $)	3 Months Ended		6 Months Ended
In Millions, unless otherwise specified	Jun. 28, 2014	Jun. 29, 2013	Jun. 28, 2014	Jun. 29, 2013
Statement of Income and Comprehensive Income [Abstract]	'	'	'	'
Tax provision (benefit) on unrealized holding gains and losses on available-for-sale investments arising during the period	$0.10	($0.10)	$0.10	$0.30
Tax provision (benefit) on reclassification adjustment for gains on available-for-sale investments recognized in net income	0	'	0	2.5
Tax provision (benefit) on unrealized holding gains and losses on hedging instruments arising during the period	'	4.1	'	4.1
Tax provision (benefit) on reclassification adjustment for losses on hedging instruments recognized in net income	-0.5	-0.5	-0.9	-1
Tax provision (benefit) on pension and other postretirement benefit liability adjustments arising during the period	-0.3	-0.1	-0.9	1.5
Tax provision (benefit) on amortization of net loss and prior service benefit included in net periodic pension cost	($0.60)	($0.90)	($1.20)	($1.80)

Consolidated_Statement_of_Cash

Consolidated Statement of Cash Flows (Unaudited) (USD $)	6 Months Ended
In Millions, unless otherwise specified	Jun. 28, 2014	Jun. 29, 2013
Operating Activities	'	'
Net income	$821.60	$613.60
Loss from discontinued operations	0	0.6
Loss on disposal of discontinued operations	0	4.2
Income from continuing operations	821.6	618.4
Adjustments to reconcile income from continuing operations to net cash provided by operating activities:	'	'
Depreciation and amortization	800.4	500.2
Change in deferred income taxes	-460.4	-65
Net gains on sale of businesses	-761.8	0
Non-cash stock-based compensation	56	43.7
Tax benefits from stock-based compensation awards	-55.6	-30.6
Non-cash charges for sale of inventories revalued at the date of acquisition	302.3	23.9
Other non-cash expenses, net	27.1	13.4
Changes in assets and liabilities, excluding the effects of acquisitions and dispositions:	'	'
Accounts receivable	-153.7	-139
Inventories	-53.8	-97.6
Other assets	258.9	-107.1
Accounts payable	3.4	33.3
Other liabilities	233.1	7.4
Contributions to retirement plans	-25.7	-22.6
Net cash provided by continuing operations	991.8	778.4
Net cash used in discontinued operations	-1.9	-1.7
Net cash provided by operating activities	989.9	776.7
Investing Activities	'	'
Acquisitions, net of cash acquired	-13,054.50	-4.7
Purchase of property, plant and equipment	-180.2	-131.6
Proceeds from sale of property, plant and equipment	12.7	3.6
Proceeds from sale of investments	65	0.5
Proceeds from sale of businesses, net of cash divested	1,048.70	0
Decrease (increase) in restricted cash	37.9	-0.5
Other investing activities, net	-3.7	-0.2
Net cash used in investing activities	-12,074.10	-132.9
Financing Activities	'	'
Net proceeds from issuance of long-term debt	4,999.60	0
Increase in commercial paper, net	305.6	0
Repayment of long-term obligations	-2,452.30	-0.7
Decrease in short-term notes payable	-18.6	-1.6
Purchases of company common stock	0	-89.8
Dividends paid	-114.7	-107.9
Net proceeds from issuance of company common stock	2,942	0
Net proceeds from issuance of company common stock under employee stock plans	108.6	172.3
Tax benefits from stock-based compensation awards	55.6	30.6
Other financing activities, net	-4.9	-0.8
Net cash provided by financing activities	5,820.90	2.1
Exchange Rate Effect on Cash	22.2	-88.8
(Decrease) Increase in Cash and Cash Equivalents	-5,241.10	557.1
Cash and Cash Equivalents at Beginning of Period	5,826	805.6
Cash and Cash Equivalents at End of Period	$584.90	$1,362.70

Consolidated_Statement_of_Shar

Consolidated Statement of Shareholders' Equity (Unaudited) (USD $)	Total	Common Stock [Member]	Capital in Excess of Par Value [Member]	Retained Earnings [Member]	Treasury Stock [Member]	Accumulated Other Comprehensive Items [Member]
In Millions, unless otherwise specified	Total	Common Stock [Member]	Capital in Excess of Par Value [Member]	Retained Earnings [Member]	Treasury Stock [Member]	Accumulated Other Comprehensive Items [Member]
Balance at Dec. 31, 2012	$15,464.70	$413.50	$10,501.10	$7,697.30	($2,996.80)	($150.40)
Balance (in shares) at Dec. 31, 2012	'	413.5	'	'	56	'
Increase (Decrease) in Stockholders' Equity [Roll Forward]	'	'	'	'	'	'
Issuance of shares under employees' and directors' stock plans (in shares)	'	4.6	'	'	0.3	'
Issuance of shares under employees' and directors' stock plans	156.9	4.6	171.6	'	-19.3	'
Stock-based compensation	43.7	'	43.7	'	'	'
Tax benefit related to employees' and directors' stock plans	28.4	'	28.4	'	'	'
Purchases of company common stock (in shares)	'	'	'	'	1.3	'
Purchases of company common stock	-89.8	'	'	'	-89.8	'
Dividends declared	-108.3	'	'	-108.3	'	'
Net income	613.6	'	'	613.6	'	'
Other comprehensive items	-305.6	'	'	'	'	-305.6
Other	-0.8	'	-0.8	'	'	'
Balance at Jun. 29, 2013	15,802.80	418.1	10,744	8,202.60	-3,105.90	-456
Balance (in shares) at Jun. 29, 2013	'	418.1	'	'	57.6	'
Balance at Dec. 31, 2013	16,856.10	369.6	8,222.60	8,753.30	-412.2	-77.2
Balance (in shares) at Dec. 31, 2013	'	369.6	'	'	7.6	'
Increase (Decrease) in Stockholders' Equity [Roll Forward]	'	'	'	'	'	'
Issuance of shares under employees' and directors' stock plans (in shares)	'	2.7	'	'	0.3	'
Issuance of shares under employees' and directors' stock plans	82	2.7	110.2	'	-30.9	'
Issuance of shares (in shares)	'	34.9	'	'	'	'
Issuance of shares	2,942.30	34.9	2,907.40	'	'	'
Stock-based compensation	56	'	56	'	'	'
Tax benefit related to employees' and directors' stock plans	55.5	'	55.5	'	'	'
Dividends declared	-120.3	'	'	-120.3	'	'
Net income	821.6	'	'	821.6	'	'
Other comprehensive items	-34.5	'	'	'	'	-34.5
Other	-0.1	'	-0.1	'	'	'
Balance at Jun. 28, 2014	$20,658.60	$407.20	$11,351.60	$9,454.60	($443.10)	($111.70)
Balance (in shares) at Jun. 28, 2014	'	407.2	'	'	7.9	'

Nature_of_Operations_and_Summa

Nature of Operations and Summary of Significant Accounting Policies	6 Months Ended
	Jun. 28, 2014
Nature of Operations and Summary of Significant Accounting Policies [Abstract]	'
Nature of Operations and Summary of Significant Accounting Policies [Text Block]	'
	Note 1. Nature of Operations and Summary of Significant Accounting Policies
	Nature of Operations
	Thermo Fisher Scientific Inc. (the company or Thermo Fisher) enables customers to make the world healthier, cleaner and safer by providing analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. Markets served include pharmaceutical and biotech companies, hospitals and clinical diagnostic labs, universities, research institutions and government agencies, as well as environmental and industrial process control settings. On February 3, 2014, the company acquired Life Technologies Corporation (Note 2).

	Interim Financial Statements
	The interim consolidated financial statements presented herein have been prepared by the company, are unaudited and, in the opinion of management, reflect all adjustments of a normal recurring nature necessary for a fair statement of the financial position at June 28, 2014, the results of operations for the three- and six-month periods ended June 28, 2014, and June 29, 2013, and the cash flows for the six-month periods ended June 28, 2014, and June 29, 2013. Interim results are not necessarily indicative of results for a full year.
	The consolidated balance sheet presented as of December 31, 2013, has been derived from the audited consolidated financial statements as of that date. The consolidated financial statements and notes are presented as permitted by Form 10-Q and do not contain all information that is included in the annual financial statements and notes of the company. The consolidated financial statements and notes included in this report should be read in conjunction with the 2013 financial statements and notes included in the company’s Current Report on Form 8-K filed with the Securities and Exchange Commission (SEC) on May 2, 2014.
	Note 1 to the consolidated financial statements for 2013 describes the significant accounting estimates and policies used in preparation of the consolidated financial statements. There have been no material changes in the company’s significant accounting policies during the six months ended June 28, 2014.

	Warranty Obligations
	Product warranties are included in other accrued expenses in the accompanying balance sheet. The changes in the carrying amount of warranty obligations are as follows:

						Six Months Ended
					June 28,			June 29,
	(In millions)					2014			2013

	Beginning Balance					$	49.8		$	48.7
		Provision charged to income					38.2			34.8
		Usage					-39.2			-37.1
		Acquisitions					7.2			—
		Adjustments to previously provided warranties, net					0.9			0.3
		Other, net					—			-0.5

	Ending Balance					$	56.9		$	46.2

	Inventories
	The components of inventories are as follows:

					June 28,				December 31,
	(In millions)						2014		2013

	Raw Materials					$	461.3		$	347.4
	Work in Process						217.2			157.7
	Finished Goods						1,255.30			989.4

	Inventories					$	1,933.80		$	1,494.50


	Property, Plant and Equipment
	Property, plant and equipment consists of the following:

					June 28,				December 31,
	(In millions)						2014		2013

	Land					$	294.9		$	212.2
	Buildings and Improvements						1,025.40			821
	Machinery, Equipment and Leasehold Improvements						2,569.20			2,047.90

	Property, Plant and Equipment, at Cost						3,889.50			3,081.10
	Less: Accumulated Depreciation and Amortization						1,417.50			1,313.70

	Property, Plant and Equipment, at Cost, Net					$	2,472.00		$	1,767.40


	Acquisition-related Intangible Assets
	Acquisition-related intangible assets are as follows:

				28-Jun-14									31-Dec-13
						Accumulated									Accumulated
	(In millions)			Gross			Amortization			Net			Gross			Amortization			Net

	Definite Lived			$	18,715.20		$	-4,937.80		$	13,777.40		$	10,121.80		$	-4,388.20		$	5,733.60
	Indefinite Lived				1,844.20			—			1,844.20			1,337.70			—			1,337.70

Acquisition-related Intangible Assets			$	20,559.40		$	-4,937.80		$	15,621.60		$	11,459.50		$	-4,388.20		$	7,071.30


Use of Estimates
The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. In addition, significant estimates were made in estimating future cash flows to assess potential impairment of assets and in determining the fair value of acquired intangible assets (Note 2) and the ultimate loss from abandoning leases at facilities being exited (Note 14). Actual results could differ from those estimates.
Recent Accounting Pronouncements

In May 2014, the FASB issued new revenue recognition guidance which provides a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and will supersede most current revenue recognition guidance. The new standard also requires significantly expanded disclosures regarding the qualitative and quantitative information of an entity's nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. The guidance is effective for the company in 2017. Early adoption is not permitted. The company is currently evaluating the impact the standard will have on its consolidated financial statements.
In April 2014, the FASB issued new guidance on reporting discontinued operations and disclosures of disposals. Under the new guidance, only disposals representing a strategic shift in operations will be presented as discontinued operations. The new guidance also requires disclosure of the pre-tax income attributable to a disposal of a significant part of the company that does not qualify for discontinued operations reporting. This guidance is effective for the company in 2015. Adoption of this standard is not expected to have a material impact on the company’s consolidated financial statements.

Acquisitions_and_Dispositions

Acquisitions and Dispositions	6 Months Ended
Acquisitions and Dispositions	Jun. 28, 2014
Acquisitions and Dispositions Disclosure	'
Acquisitions and Dispositions [Text Block]	'
	Note 2. Acquisitions and Dispositions
	The company’s acquisitions have historically been made at prices above the fair value of the acquired identifiable assets, resulting in goodwill, due to expectations of the synergies that will be realized by combining the businesses. These synergies include the elimination of redundant facilities, functions and staffing; use of the company’s existing commercial infrastructure to expand sales of the acquired businesses’ products; and use of the commercial infrastructure of the acquired businesses to cost-effectively expand sales of company products.
	Acquisitions have been accounted for using the purchase method of accounting, and the acquired companies’ results have been included in the accompanying financial statements from their respective dates of acquisition. Acquisition transaction costs are recorded in selling, general and administrative expenses as incurred.

	2014
	On February 3, 2014, the company completed the acquisition of Life Technologies Corporation within the Life Sciences Solutions segment for a total purchase price of $15.30 billion, net of cash acquired, including the assumption of $2.28 billion of debt. The company issued debt and common stock in late 2013 and early 2014 to partially fund the acquisition (Notes 9 and 11). Life Technologies provides innovative products and services to customers conducting scientific research and genetic analysis, as well as those in applied markets, such as forensics and food safety testing. The acquisition of Life Technologies extends customer reach and broadens the company’s offerings in biosciences; genetic, medical and applied sciences; and bioproduction. Life Technologies’ revenues totaled $3.87 billion in 2013. The purchase price exceeded the fair value of the identifiable net assets and, accordingly, $7.12 billion was allocated to goodwill, substantially none of which is tax deductible.
	In addition, in 2014, the company acquired an animal health diagnostics company within the Life Sciences Solutions segment for $34 million, net of cash acquired.

			The components of the purchase price and net assets acquired for 2014 acquisitions are as follows:

	(In millions)			Life Technologies		Other			Total

	Purchase Price
		Cash paid		$	13,487.30	$	41.7		$	13,529.00
		Debt assumed			2,279.70		—			2,279.70
		Purchase price payable			—		4			4
		Cash acquired			-463		-11.5			-474.5

				$	15,304.00	$	34.2		$	15,338.20

	Net Assets Acquired
		Current assets		$	1,768.10	$	18.4		$	1,786.50
		Property, plant and equipment			752.3		1.1			753.4
		Definite-lived intangible assets:
			Customer relationships		5,864.00		5.5			5,869.50
			Product technology		2,624.60		5.5			2,630.10
			Tradenames and other		240.6		—			240.6
		Indefinite-lived intangible assets:
			Tradenames		448.2		—			448.2
			In-process research and development		58.4		—			58.4
		Goodwill			7,123.50		12.5			7,136.00
		Other assets			251.8		0.1			251.9
		Liabilities assumed			-3,827.50		-8.9			-3,836.40

				$	15,304.00	$	34.2		$	15,338.20


	The weighted-average amortization periods for intangible assets acquired in 2014 are 16 years for customer relationships, 11 years for product technology and 9 years for definite-lived tradenames and other. The weighted average amortization period for all definite-lived intangible assets acquired in 2014 is 14 years.
	The net assets acquired have been recorded based on estimates of fair value. The company is not aware of any incomplete aspects of the purchase price allocation for Life Technologies except for the ongoing evaluation of the value attributable to various tradenames as of the acquisition date as well as their designation as indefinite-lived or definite-lived. The company expects the evaluation and any resulting changes to the purchase price allocation to be completed in the second half of 2014.

	Unaudited Pro Forma Information
	The company acquired Life Technologies in February 2014. Revenues of Life Technologies after the date of acquisition are included in the accompanying statement of income and totaled approximately $0.96 billion and $1.62 billion in the three and six months ended June 28, 2014, respectively. Immediately upon the closing of the acquisition, the company began integrating Life Technologies and as such the legacy and acquired businesses are now sharing various selling, general and administrative functions. As a result, computing a separate measure of Life Technologies’ stand-alone profitability for periods after the acquisition date is not practical.
	Had the acquisition of Life Technologies been completed as of the beginning of 2013, the company’s pro forma results for 2014 and 2013 would have been as follows:

						Three Months Ended			Six Months Ended
						June 29,		June 28,			June 29,
	(In millions except per share amounts)					2013			2014		2013

	Revenues					$	4,153.60		$	8,501.50	$	8,268.60

	Income from Continuing Operations					$	319.8		$	1,114.90	$	326.2

	Net Income					$	319.6		$	1,114.90	$	321.4

	Earnings per Share from Continuing Operations:
		Basic				$	0.81		$	2.8	$	0.83
		Diluted				$	0.8		$	2.77	$	0.82

	Earnings per Share:
		Basic				$	0.81		$	2.8	$	0.82
		Diluted				$	0.8		$	2.77	$	0.81


Pro forma results include non-recurring pro forma adjustments that were directly attributable to the business combination, as follows:

Pre tax charge to selling, general and administrative expenses of $208.2 million in the six months ended June 29, 2013, for acquisition-related transaction costs incurred by the company and Life Technologies;
Pre tax charge to cost of revenues of $55.4 million and $301.4 million in the three and six months ended June 29, 2013, for the sale of Life Technologies inventories revalued at the date of acquisition;
Pre tax charge of $91.7 million in the six months ended June 29, 2013, for monetizing equity awards held by Life Technologies’ employees at the date of acquisition;
Pre tax charge of $37.6 million in the six months ended June 29, 2013, to conform the accounting policies of Life Technologies with the company's accounting policies; and
Pre tax reduction of revenues of $5.2 million, $4.7 million and $16.8 million in the three months ended June 29, 2013 and the six months ended June 28, 2014 and June 29, 2013, respectively, for revaluing Life Technologies’ deferred revenue obligations to fair value.

These pro forma results of operations have been prepared for comparative purposes only, and they do not purport to be indicative of the results of operations that actually would have resulted had the acquisition occurred on the date indicated or that may result in the future.
The company’s results would not have been materially different from its pro forma results had the company’s other 2014 acquisition occurred at the beginning of 2013.
Dispositions
On July 17, 2014, the company announced that it had entered an agreement to sell its Cole-Parmer specialty channel business, part of the Laboratory Products and Services segment, for $480 million in cash. The transaction is expected to close in the third quarter of 2014, subject to customary closing conditions and applicable regulatory approvals. Revenues and operating income of the business to be sold were approximately $232 million and $43 million, respectively, for the year ended December 31, 2013 and $119 million and $23 million, respectively, in the first half of 2014.
The assets and liabilities of the Cole-Parmer business were as follows at June 28, 2014:

	June 28,
(In millions)		2014

Current Assets		$	39.5
Long-term Assets			400.3
Current Liabilities			15.5
Long-term Liabilities			84.1


On March 21, 2014, the company sold its sera and media, gene modulation and magnetic beads businesses to GE Healthcare for $1.05 billion, net of cash divested, or $0.8 billion of after-tax proceeds. The businesses fell principally in the Life Sciences Solutions segment. Divestiture of these businesses was a condition to obtaining antitrust approval for the Life Technologies acquisition. Revenues and operating income of the businesses sold were approximately $250 million and $64 million, respectively, for the year ended December 31, 2013 and $61 million and $12 million, respectively, in 2014 through the date of sale. The sale of these businesses resulted in a pre-tax gain of approximately $761 million, included in restructuring and other costs (income), net.
The assets and liabilities of the businesses sold in March 2014 were as follows at December 31, 2013:

	December 31,
(In millions)		2013

Current Assets		$	74.3
Long-term Assets			229.3
Current Liabilities			6.4
Long-term Liabilities			22

Business_Segment_Information

Business Segment Information	6 Months Ended
Business Segment Information	Jun. 28, 2014
Business Segments	'
Business Segment Information [Text Block]	'
	Note 3. Business Segment and Geographical Information
	With the completion of the Life Technologies acquisition, the company established a new reporting segment, called Life Sciences Solutions. Effective January 1, 2014, the company’s financial performance is reported in four segments reflecting the following changes:

	The new Life Sciences Solutions segment consists of the majority of the former Life Technologies businesses and Thermo Fisher biosciences businesses.

	Thermo Fisher’s global chemicals business has moved from the biosciences business in the Analytical Technologies segment to the Laboratory Products and Services segment.

	Thermo Fisher’s Analytical Technologies segment has been renamed the Analytical Instruments segment to reflect the transfer of the biosciences businesses to other segments, as mentioned above.

	Two small specialty diagnostics businesses within Life Technologies have become part of the Specialty Diagnostics segment.

	Prior period segment information has been reclassified to reflect these transfers. As Life Technologies was acquired on February 3, 2014, its results are not included in the company’s results prior to that date. A description of each segment follows.
	Life Sciences Solutions: provides a portfolio of reagents, instruments and consumables used in biological and medical research, discovery and production of new drugs and vaccines as well as diagnosis of disease. These products and services are used by customers in life science research, drug discovery and diagnostics markets.
	Analytical Instruments: provides a broad offering of instruments, consumables, software and services that are used for a range of applications in the laboratory, on the production line and in the field. These products and services are used by customers in pharmaceutical, biotechnology, academic, government, environmental and other research and industrial markets, as well as the clinical laboratory.
	Specialty Diagnostics: provides a wide range of diagnostic test kits, reagents, culture media, instruments and associated products used to increase the speed and accuracy of diagnoses. These products are used primarily by customers in healthcare, clinical, pharmaceutical, industrial and food safety laboratories.
	Laboratory Products and Services: provides virtually everything needed for the laboratory, including a combination of self-manufactured and sourced products and an extensive service offering. These products and services are used by customers in pharmaceutical, biotechnology, academic, government and other research and industrial markets, as well as the clinical laboratory.
	The company’s management evaluates segment operating performance based on operating income before certain charges/credits to cost of revenues and selling, general and administrative expenses, principally associated with acquisition accounting; restructuring and other costs/income including costs arising from facility consolidations such as severance and abandoned lease expense and gains and losses from the sale of real estate and product lines; and amortization of acquisition-related intangible assets. The company uses this measure because it helps management understand and evaluate the segments’ core operating results and facilitates comparison of performance for determining compensation.

	Business Segment Information

					Three Months Ended						Six Months Ended
				June 28,			June 29,			June 28,			June 29,
	(In millions)				2014			2013			2014			2013

	Revenues
		Life Sciences Solutions			$	1,103.10		$	181		$	1,938.60		$	353.6
		Analytical Instruments				793.4			761			1,563.30			1,501.10
		Specialty Diagnostics				855.1			793.6			1,668.80			1,599.20
		Laboratory Products and Services				1,699.40			1,595.00			3,289.90			3,151.30
		Eliminations				-129.1			-90.5			-235.2			-173.6

			Consolidated revenues			4,321.90			3,240.10			8,225.40			6,431.60

	Segment Income
		Life Sciences Solutions (a)				299.1			43.5			543.7			84.5
		Analytical Instruments (a)				130.4			125.3			261.3			245.8
		Specialty Diagnostics (a)				236.4			216.3			457.4			439.2
		Laboratory Products and Services (a)				257.7			238.7			491.7			469.4

			Subtotal reportable segments (a)			923.6			623.8			1,754.10			1,238.90

		Cost of revenues charges				-156.1			-13.1			-324.6			-26.3
		Selling, general and administrative charges, net				-14.9			-22.6			-97.7			-23.9
		Restructuring and other (costs) income, net				-60.9			-21.5			521.3			-43
		Amortization of acquisition-related intangible assets				-343.6			-191.2			-629.5			-383.2

			Consolidated operating income			348.1			375.4			1,223.60			762.5
		Other expense, net (b)				-111.6			-95.4			-212.7			-139.6

		Income from continuing operations before income taxes			$	236.5		$	280		$	1,010.90		$	622.9

	Depreciation
		Life Sciences Solutions			$	36.3		$	4.1		$	60.3		$	8.2
		Analytical Instruments				9.2			9.8			19.6			20
		Specialty Diagnostics				19.2			18.1			38			36.6
		Laboratory Products and Services				26.5			26			53			52.2

			Consolidated depreciation		$	91.2		$	58		$	170.9		$	117

	(a)	Represents operating income before certain charges to cost of revenues and selling, general and administrative expenses; restructuring and other costs, net; and amortization of acquisition-related intangibles.

	(b)	The company does not allocate other expense, net to its segments.

Other_Expense_Net

Other Expense, Net	6 Months Ended
Other Expense, Net	Jun. 28, 2014
Other Expense, Net Disclosure	'
Other Expense, Net [Text Block]	'
	Note 4. Other Expense, Net
	The components of other expense, net, in the accompanying statement of income are as follows:

			Three Months Ended						Six Months Ended
		June 28,			June 29,			June 28,			June 29,
	(In millions)		2014			2013			2014			2013

	Interest Income		$	16		$	7.1		$	27.9		$	14.3
	Interest Expense			-129.1			-64.4			-246.9			-128.8
	Other Items, Net			1.5			-38.1			6.3			-25.1

	Other Expense, Net		$	-111.6		$	-95.4		$	-212.7		$	-139.6


	Other Items, Net
	In the first six months of 2014, other items, net includes $5 million of gains from the sale of equity and available-for-sale investments. In the first six months of 2013, other items, net includes $41 million of charges related to amortization of fees paid to obtain bridge financing commitments related to the acquisition of Life Technologies, offset in part by a $2 million gain from additional proceeds from the prior sale of an equity investment. In the first quarter of 2013, the company irrevocably contributed appreciated available-for-sale investments that had a fair value of $27 million to two of its U.K. defined benefit plans, resulting in realization of a previously unrecognized gain of $11 million.

Stockbased_Compensation_Expens

Stockbased Compensation Expense	6 Months Ended
Stockbased Compensation Expense	Jun. 28, 2014
Stock-based Compensation Expense Disclosure [Abstract]	'
Stock-based Compensation Expense [Text Block]	'
	Note 5. Stock-based Compensation Expense

		The components of stock-based compensation expense are as follows:

				Three Months Ended						Six Months Ended
			June 28,			June 29,			June 28,			June 29,
	(In millions)			2014			2013			2014			2013

	Stock Option Awards			$	11.7		$	10.6		$	22.4		$	20.2
	Restricted Unit Awards				19.1			12.7			33.6			23.5

	Total Stock-based Compensation Expense			$	30.8		$	23.3		$	56		$	43.7


	As of June 28, 2014, there was $104 million of total unrecognized compensation cost related to unvested stock options granted. The cost is expected to be recognized through 2018 with a weighted average amortization period of 2.7 years.

	As of June 28, 2014, there was $142 million of total unrecognized compensation cost related to unvested restricted stock unit awards. The cost is expected to be recognized through 2017 with a weighted average amortization period of 2.5 years.

	During the first six months of 2014, the company made equity compensation grants to employees consisting of 1.0 million service- and performance-based restricted stock units and options to purchase 2.5 million shares.
	Certain pre-acquisition equity awards of Life Technologies were converted to rights to receive future cash payments over the remaining vesting period. In addition to stock-based compensation, which is included in the above table, in the three- and six-month periods ended June 28, 2014, the company recorded expense for cash-in-lieu of equity of $10.0 million and $17.1 million, respectively, related to these arrangements.

Pension_and_Other_Postretireme

Pension and Other Postretirement Benefit Plans	6 Months Ended
Pension and Other Postretirement Benefit Plans	Jun. 28, 2014
General Discussion of Pension and Other Postretirement Benefits [Abstract]	'
Pension and Other Postretirement Benefits Disclosure [Text Block]	'
	Note 6. Pension and Other Postretirement Benefit Plans

	Employees of a number of the company’s non-U.S. and certain U.S. subsidiaries participate in defined benefit pension plans covering substantially all full-time employees at those subsidiaries. Some of the plans are unfunded, as permitted under the plans and applicable laws. The company also maintains postretirement healthcare programs at several acquired businesses where certain employees are eligible to participate. The costs of the postretirement healthcare programs are funded on a self-insured and insured-premium basis.

	Net periodic benefit costs for the company’s defined benefit pension plans include the following components:

			Three Months Ended						Six Months Ended
		June 28,			June 29,			June 28,			June 29,
	(In millions)		2014			2013			2014			2013

	Service Cost - Benefits Earned		$	5		$	5.8		$	9.6		$	9.4
	Interest Cost on Benefit Obligation			23.5			11.9			43.6			23.9
	Expected Return on Plan Assets			-25.1			-13.2			-46.2			-26.4
	Amortization of Net Loss			2.1			2.9			4			5.7
	Amortization of Prior Service Benefit			-0.1			-0.1			-0.1			-0.2
	Special Termination Benefits			—			0.4			—			0.5

	Net Periodic Benefit Cost		$	5.4		$	7.7		$	10.9		$	12.9

Income_Taxes

Income Taxes	6 Months Ended
Income Taxes	Jun. 28, 2014
Income Taxes Disclosure [Abstract]	'
Income Taxes [Text Block]	'
	Note 7. Income Taxes

			The provision for income taxes in the accompanying statement of income differs from the provision calculated
	by applying the statutory federal income tax rate of 35% to income from continuing operations before provision for
	income taxes due to the following:

					Six Months Ended
				June 28,			June 29,
	(In millions)				2014			2013

	Provision for Income Taxes at Statutory Rate				$	353.8		$	218

	Increases (Decreases) Resulting From:
		Foreign rate differential				-60.8			-119.8
		Impact of change in tax laws and apportionment on deferred taxes				-25.9			-1.8
		Foreign and research and development tax credits				-59.4			-79.5
		Manufacturing deduction				-8.9			-13.4
		State income taxes, net of federal tax				23.1			-1.8
		Nondeductible expenses				3.3			3.3
		Provision of tax reserves, net				25.3			—
		Basis difference on disposal of businesses				-61.9			—
		Other, net				0.7			-0.5

					$	189.3		$	4.5


	The company’s unrecognized tax benefits increased to $259.8 million at June 28, 2014, from $134.2 million at December 31, 2013. Of the total increase, $100.3 million resulted from the acquisition of Life Technologies and $54.4 million resulted from the provision of tax reserves, primarily related to the sale of the divested businesses and a tax matter in a foreign jurisdiction, offset in part by a reduction of $29.1 million from resolution of a tax matter for which a reserve had previously been established.

Earnings_Per_Share

Earnings Per Share	6 Months Ended
Earnings Per Share	Jun. 28, 2014
Earnings per Share	'
Earnings per Share [Text Block]	'
	Note 8. Earnings per Share

				Three Months Ended						Six Months Ended
			June 28,			June 29,			June 28,			June 29,
	(In millions except per share amounts)			2014			2013			2014			2013

	Income from Continuing Operations			$	278.5		$	277.6		$	821.6		$	618.4
	Loss from Discontinued Operations				—			-0.2			—			-0.6
	Loss on Disposal of Discontinued Operations, Net				—			—			—			-4.2

	Net Income			$	278.5		$	277.4		$	821.6		$	613.6

	Basic Weighted Average Shares				399.4			360			396.3			359
	Plus Effect of:
		Equity forward arrangement			—			—			0.3			—
		Stock options and restricted units			3.7			3.5			4.1			3.6

	Diluted Weighted Average Shares				403.1			363.5			400.7			362.6

	Basic Earnings per Share:
		Continuing operations		$	0.7		$	0.77		$	2.07		$	1.72
		Discontinued operations			—			—			—			-0.01

				$	0.7		$	0.77		$	2.07		$	1.71

	Diluted Earnings per Share:
		Continuing operations		$	0.69		$	0.76		$	2.05		$	1.71
		Discontinued operations			—			—			—			-0.01

				$	0.69		$	0.76		$	2.05		$	1.69


	Options to purchase 2.5 million, 1.8 million, 2.4 million and 1.8 million shares of common stock were not included in the computation of diluted earnings per share for the second quarter of 2014 and 2013 and first six months of 2014 and 2013, respectively, because their effect would have been antidilutive.

Debt_and_Other_Financing_Arran

Debt and Other Financing Arrangements	6 Months Ended
Debt and Other Financing Arrangements	Jun. 28, 2014
Debt And Other Financing Arrangements Disclosure [Abstract]	'
Debt and Other Financing Arrangements [Text Block]	'
	Note 9. Debt and Other Financing Arrangements

			Effective
			Interest Rate at	June 28,			December 31,
	(Dollars in millions)		28-Jun-14		2014		2013

	Commercial Paper		0.55%		$	556.2	$	250
	Term Loan		1.62%			2,850.00		—
	2.05% Senior Notes, Due 2014					—		300
	3.25% Senior Notes, Due 2014		1.57%			400		400
	4.40% Senior Notes, Due 2015		0.75%			500		—
	3.20% Senior Notes, Due 2015		1.58%			450		450
	5.00% Senior Notes, Due 2015		5.13%			250		250
	3.50% Senior Notes, Due 2016		1.05%			400		—
	3.20% Senior Notes, Due 2016		3.21%			900		900
	2.25% Senior Notes, Due 2016		2.29%			1,000.00		1,000.00
	1.30% Senior Notes, Due 2017		0.91%			900		900
	1.85% Senior Notes, Due 2018		1.85%			500		500
	2.40% Senior Notes, Due 2019		2.44%			900		900
	6.00% Senior Notes, Due 2020		2.98%			750		—
	4.70% Senior Notes, Due 2020		4.70%			300		300
	5.00% Senior Notes, Due 2021		3.25%			400		—
	4.50% Senior Notes, Due 2021		4.58%			1,000.00		1,000.00
	3.60% Senior Notes, Due 2021		4.29%			1,100.00		1,100.00
	3.15% Senior Notes, Due 2023		3.21%			800		800
	4.15% Senior Notes, Due 2024		4.07%			1,000.00		1,000.00
	5.30% Senior Notes, Due 2044		5.30%			400		400
	Other					44.1		41.9

	Total Borrowings at Par Value					15,400.30		10,491.90
		Fair Value Hedge Accounting Adjustments				7.3		12.9
		Unamortized Premium (Discount), Net				169.5		-17.5

	Total Borrowings at Carrying Value					15,577.10		10,487.30
		Less: Short-term Obligations and Current Maturities				3,075.10		987.7

	Long-term Obligations				$	12,502.00	$	9,499.60


	The effective interest rates for the fixed-rate debt include the stated interest on the notes, the accretion of any discount or amortization of any premium and, if applicable, adjustments related to hedging.
	See Note 12 for fair value information pertaining to the company’s long-term obligations.

	Credit Facilities
	The company has a revolving credit facility with a bank group that provides for up to $1.50 billion of unsecured multi-currency revolving credit. The facility expires in July 2018. The agreement calls for interest at either a LIBOR-based rate or a rate based on the prime lending rate of the agent bank, at the company’s option. The agreement contains affirmative, negative and financial covenants, and events of default customary for financings of this type. The financial covenant requires the company to maintain a Consolidated Leverage Ratio of debt to EBITDA (as defined in the agreement) below 5.5 to 1.0 until August 2014 and decreasing, based on the passage of time, to 3.5 to 1.0, by August 2015 and an Interest Coverage Ratio of EBITDA (as defined in the agreement) to interest expense of 3.0 to 1.0. The credit agreement permits the company to use the facility for working capital; acquisitions; repurchases of common stock, debentures and other securities; the refinancing of debt; and general corporate purposes. The credit agreement allows for the issuance of letters of credit, which reduces the amount available for borrowing. If the company borrows under this facility, it intends to leave undrawn an amount equivalent to outstanding commercial paper to provide a source of funds in the event that commercial paper markets are not available. As of June 28, 2014, no borrowings were outstanding under the facility, although available capacity was reduced by approximately $58 million as a result of outstanding letters of credit.
	Commercial Paper Program
	The company has a U.S. commercial paper program pursuant to which it may issue and sell unsecured, short-term promissory notes (CP Notes). Maturities may not exceed 397 days from the date of issue and the CP Notes rank pari passu with all of the company’s other unsecured and unsubordinated indebtedness. CP Notes are issued on a private placement basis under customary terms in the commercial paper market and are not redeemable prior to maturity nor subject to voluntary prepayment. CP Notes are issued at a discount from par, or, alternatively, are sold at par and bear varying interest rates on a fixed or floating basis. As of June 28, 2014, outstanding borrowings under this program were $556 million, with a weighted average remaining period to maturity of 37 days. The weighted average interest rate on the outstanding CP Notes as of June 28, 2014 was 0.55%.
	Term Loan
	In connection with the acquisition of Life Technologies, the company entered into a 3-year unsecured term loan agreement. The term loan agreement calls for interest at either a LIBOR-based rate or a rate based on the prime lending rate of the agent bank, at the company’s option. The term loan agreement contains affirmative, negative and financial covenants, and events of default customary for financings of this type. The financial covenants require the company to maintain a Consolidated Leverage Ratio of debt to EBITDA (as defined in the agreements) below 5.5 to 1.0 until August 2014 and decreasing, based on the passage of time, to 3.5 to 1.0, by August 2015. The company must also maintain a minimum interest coverage ratio of 3.0 to 1.0. As of June 28, 2014, outstanding borrowings under the term loan agreement were $2.85 billion. The company is required to make minimum periodic payments totaling $375 million, $1.00 billion and $1.00 billion in the remainder of 2014 and in 2015 and 2016, respectively. The remaining balance is due in February 2017. Borrowings may be prepaid without penalty.
	Senior Notes
	Interest on each of the senior notes is payable semi-annually. Each of the notes may be redeemed at any time at a redemption price of 100% of the principal amount plus a specified make-whole premium plus accrued interest. The company is subject to certain affirmative and negative covenants under the indentures governing the senior notes, the most restrictive of which limits the ability of the company to pledge principal properties as security under borrowing arrangements.
	The 4.40% Senior Notes due 2015, 3.50% Senior Notes due 2016, 6.00% Senior Notes due 2020 and 5.00% Senior Notes due 2021 were assumed by the company in connection with the Life Technologies acquisition. The fair value of these senior notes on the date of acquisition exceeded the par value by $207 million which was recorded as part of the carrying value of the underlying debt and will be amortized as a reduction of interest expense over the remaining terms of the respective debt instruments. This adjustment does not affect cash interest payments.
	Interest Rate Swap Arrangements
	In 2013, upon the issuance of $900 million principal amount of 1.30% Senior Notes due 2017, the company entered into LIBOR-based interest rate swap arrangements with various banks. The aggregate amount of the swaps is equal to the principal amount of the 1.30% Notes and the payment dates of the swaps coincide with the payment dates of the 1.30% Notes. The swap contracts provide for the company to pay a variable interest rate of one-month LIBOR plus a spread of 0.6616% (0.8126% at June 28, 2014) and to receive a fixed rate of 1.30%. The variable interest rate resets monthly. The swaps have been accounted for as a fair value hedge of the 1.30% Notes. See Note 12 for additional information.

Commitments_and_Contingencies

Commitments and Contingencies	6 Months Ended
Commitments and Contingencies	Jun. 28, 2014
Commitments and Contingencies Disclosure [Abstract]	'
Commitments and Contingencies Disclosure [Text Block]	'
	Note 10. Commitments and Contingencies

	There are various lawsuits and claims pending against the company involving product liability, intellectual property, contract, commercial and other issues. The company establishes a liability that is an estimate of amounts needed to pay damages in the future for events that have already occurred. The company accrues the most likely amount or at least the minimum of the range of probable loss when a range of probable loss can be estimated. The accrued liabilities are based on management’s judgment as to the probability of losses for asserted and unasserted claims and, where applicable, actuarially determined estimates. The reserve estimates are adjusted as additional information becomes known or payments are made.

	The company records estimated amounts due from insurers related to certain product liabilities as an asset. Although the company believes that the amounts reserved and estimated recoveries are probable and appropriate based on available information, including actuarial studies of loss estimates, the process of estimating losses and insurance recoveries involves a considerable degree of judgment by management and the ultimate amounts could vary materially. Insurance contracts do not relieve the company of its primary obligation with respect to any losses incurred. The collectability of amounts due from its insurers is subject to the solvency and willingness of the insurer to pay, as well as the legal sufficiency of the insurance claims. Management monitors the financial condition and ratings of its insurers on an ongoing basis.

	The company is currently involved in various stages of investigation and remediation related to environmental matters. The company cannot predict all potential costs related to environmental remediation matters and the possible impact on future operations given the uncertainties regarding the extent of the required cleanup, the complexity and interpretation of applicable laws and regulations, the varying costs of alternative cleanup methods and the extent of the company’s responsibility. Expenses for environmental remediation matters related to the costs of permit requirements and installing, operating and maintaining groundwater-treatment systems and other remedial activities related to historical environmental contamination at the company’s domestic and international facilities were not material in any period presented. The company records accruals for environmental remediation liabilities, based on current interpretations of environmental laws and regulations, when it is probable that a liability has been incurred and the amount of such liability can be reasonably estimated. The company calculates estimates based upon several factors, including reports prepared by environmental specialists and management’s knowledge of and experience with these environmental matters. The company includes in these estimates potential costs for investigation, remediation and operation and maintenance of cleanup sites.

	On February 3, 2014, the company acquired Life Technologies. Life Technologies and its subsidiaries are party to several lawsuits in which plaintiffs claim infringement of their intellectual property, including the following:
	On June 6, 2004, Enzo Biochem, Enzo Life Sciences and Yale University filed a complaint against Life Technologies in United States District Court for the District of Connecticut. The plaintiffs allege patent infringement by Applera’s labeled DNA terminator products used in DNA sequencing and fragment analysis. The plaintiff sought damages for alleged willful infringement, attorneys’ fees, costs, prejudgment interest, and injunctive relief. In November 2012, the jury awarded damages of $48.5 million. Prejudgment interest of $12.4 million was also granted. The $60.9 million judgment and interest was accrued by Life Technologies and the liability was assumed by the company as of the date of the acquisition. The case is currently on appeal to the United States Court of Appeals for the Federal Circuit.
	On January 30, 2012, Enzo Life Sciences filed a complaint against Life Technologies in United States District Court for the District of Delaware. The plaintiff alleges patent infringement by Life Technologies’ Taqman probes and assays, Dynabead oligo-dT beads, NCode oligonucleotide array products, Ion Torrent beads and chips and SOLiD beads and chips. The plaintiff seeks damages for alleged willful infringement, attorneys’ fees, costs, prejudgment interest and injunctive relief.
	On May 26, 2010, Promega Corp. & Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften EV filed a complaint against Life Technologies in the United States District Court for the Western District of Wisconsin. The plaintiffs allege patent infringement by sales and uses of Applied Biosystems’ short tandem repeat DNA identification products outside the scope of a 2006 license agreement. The plaintiff sought damages for alleged willful infringement, attorneys’ fees, costs, prejudgment interest, and injunctive relief. Although a jury initially found willful infringement and assessed damages at $52 million, the District Court subsequently overturned the verdict on the grounds that the plaintiff had failed to prove infringement. The District Court entered judgment in favor of Life Technologies, and the case is currently on appeal to the United States Court of Appeals for the Federal Circuit. The $52 million award was accrued by Life Technologies and the liability was assumed by the company as of the date of the acquisition.
	On September 29, 2009, Life Technologies filed a complaint against Illumina, Inc. and Solexa, Inc. in the United States District Court for the District of Delaware alleging infringement of patents relating to clonal amplification of nucleic acids by Illumina’s next generation Genome Analyzer, HiSeq, and MiSeq DNA sequencing systems. Illumina asserted counterclaims in that case alleging infringement of patents relating to optical tracking, generating linked pairs of nucleic acid segments, and genome-wide variation analysis by Life Technologies’ next generation SOLiD sequencing system and Ion Torrent’s semiconductor sequencing system. On April 6, 2011, the case was transferred to the United States District Court for the Southern District of California. Life Technologies seeks damages for alleged willful infringement, attorneys’ fees, costs, pre- and post-judgment interest, and injunctive relief. On its counterclaims, Illumina seeks damages for alleged infringement, attorneys’ fees, costs, pre- and post-judgment interest, and injunctive relief. Final judgment of non-infringement in Illumina’s favor was entered on April 28, 2014, and Life Technologies filed an appeal from that judgment with the United States Court of Appeals for the Federal Circuit.
	On December 27, 2011, Illumina Inc. filed a complaint against Life Technologies in the United States District Court for the Southern District of California alleging infringement of a patent relating to methods for making bead arrays by Ion Torrent’s semiconductor sequencing systems. Plaintiff seeks damages for alleged willful infringement, attorneys’ fees, costs, pre- and post-judgment interest, and injunctive relief.
	On April 26, 2012, Esoterix Genetic Laboratories filed a complaint against Life Technologies in the United States District Court for the Middle District of North Carolina alleging infringement of patents relating to detection of subpopulations of cells with mutated sequences and multiplexed DNA amplification by Life Technologies’ OpenArray systems, next generation SOLiD sequencing system, and Ion Torrent semiconductor sequencing systems. Plaintiff seeks damages for alleged willful infringement, attorneys’ fees, costs, prejudgment interest, and injunctive relief.
	On October 31, 2012, Esoterix Genetic Laboratories and The Johns Hopkins University filed a complaint against Life Technologies in the United States District Court for the Middle District of North Carolina alleging infringement of patents relating to methods of determining a ratio of genetic sequences in a population of genetic sequences and methods of determining allelic imbalances in a biological sample by Life Technologies’ OpenArray systems, next generation SOLiD sequencing system, and Ion Torrent semiconductor sequencing systems. Plaintiffs seek damages for alleged willful infringement, attorneys’ fees, costs, prejudgment interest, and injunctive relief.
	On June 3, 2013, Unisone Strategic IP filed a complaint against Life Technologies in the United States District Court for the Southern District of California alleging patent infringement by Life Technologies’ supply chain management system software, which operates with product “supply centers” installed at customer sites. Plaintiff seeks damages for alleged willful infringement, attorneys’ fees, costs, and injunctive relief.
	An unfavorable outcome that differs materially from current reserve estimates for one or more of the matters described above could have a material adverse effect on the company’s results of operations, financial position or cash flows.

Comprehensive_Income_and_Share

Comprehensive Income and Shareholders Equity	6 Months Ended
Comprehensive Income and Shareholders Equity	Jun. 28, 2014
Comprehensive Income and Shareholders Equity Disclosure [Abstract]	'
Comprehensive Income and Shareholders Equity [Text Block]	'
	Note 11. Comprehensive Income and Shareholders’ Equity
	Comprehensive Income
	Comprehensive income combines net income and other comprehensive items. Other comprehensive items represent certain amounts that are reported as components of shareholders’ equity in the accompanying balance sheet.
	Changes in each component of accumulated other comprehensive items, net of tax are as follows:

	(In millions)				Currency Translation Adjustment		Unrealized Gains (Losses) on Available-for-Sale Investments			Unrealized Gains (Losses) on Hedging Instruments			Pension and Other Postretirement Benefit Liability Adjustment		Total

	Balance at December 31, 2013				$	112	$	1.3		$	-23.9		$	-166.6	$	-77.2
		Other comprehensive income (loss) before reclassifications				-36.4		1.8			—			-2.6		-37.2
		Amounts reclassified from accumulated other comprehensive items				—		-1.4			1.5			2.6		2.7

			Net other comprehensive items			-36.4		0.4			1.5			—		-34.5

	Balance at June 28, 2014				$	75.6	$	1.7		$	-22.4		$	-166.6	$	-111.7


	The amounts reclassified out of accumulated other comprehensive items are as follows:

										Six Months Ended
						Affected Line Item in the			June 28,			June 29,
	(In millions)					Statement of Income				2014			2013

	Amounts Reclassified From Accumulated Other Comprehensive Items
		Unrealized gains and losses on available-for-sale investments:
			Realized gain on sale or transfer of available-for- sale investments			Other Expense, Net				$	-1.4		$	-10.5
			Tax provision			Provision for Income Taxes					—			2.5

											-1.4			-8

		Unrealized gains and losses on hedging instruments:
			Realized loss on interest rate swaps and locks			Other Expense, Net					2.4			2.6
			Tax benefit			Provision for Income Taxes					-0.9			-1

											1.5			1.6

		Pension and other postretirement benefit liability adjustment:
			Amortization of actuarial losses			Net Periodic Benefit Cost -					4			5.8
			Amortization of prior service benefit			see Note 6 for details					-0.2			-0.2

				Total before tax							3.8			5.6
			Tax benefit			Provision for Income Taxes					-1.2			-1.8

											2.6			3.8

				Total reclassifications						$	2.7		$	-2.6


	Equity Forward Agreements
	In June 2013, in anticipation of the acquisition of Life Technologies, the company entered into equity forward agreements. The use of the equity forward agreements substantially eliminated future equity market price risk by fixing a common equity offering sales price under the then existing market conditions, while mitigating share dilution from the offering by postponing the actual issuance of common stock until the funds were needed for the Life Technologies acquisition.
	Upon settlement of the agreements, in January 2014, the company issued and delivered 29.6 million shares of its common stock at the then applicable forward sale price of $82.5342 per share.
	On February 3, 2014, the company issued 5.3 million shares of its common stock at a price of $94.85 per share to settle a private placement subscription agreement that was contingent on the closing of the Life Technologies acquisition.
	The equity forward and subscription agreements had no initial fair value as they were entered into at the then market price of the common stock. The company did not receive any proceeds from the sale of common stock until the agreements were settled. Upon settlement, the proceeds were recorded in equity. Prior to their settlement, to the extent that the equity forward agreements were dilutive, they have been reflected in the company’s diluted earnings per share calculations using the treasury stock method. Prior to closing, the subscription agreement was not potentially dilutive to the company’s diluted earnings per share calculations due to its contingent nature.

Fair_Value_Measurements_and_Fa

Fair Value Measurements and Fair Value Of Financial Instruments	6 Months Ended
	Jun. 28, 2014
Fair Value Measurements and Fair Value of Financial Instruments Disclosure	'
Fair Value Measurements and Fair Value of Financial Instruments [Text Block]	'
	Note 12. Fair Value Measurements and Fair Value of Financial Instruments
	Fair Value Measurements
	The company uses the market approach technique to value its financial instruments and there were no changes in valuation techniques during 2014. The company’s financial assets and liabilities carried at fair value are primarily comprised of investments in money market funds; derivative contracts, insurance contracts, mutual funds holding publicly traded securities and other investments in unit trusts held as assets to satisfy outstanding deferred compensation and retirement liabilities; and acquisition-related contingent consideration.
	The fair value accounting guidance requires that assets and liabilities carried at fair value be classified and disclosed in one of the following three categories:
	Level 1: Quoted market prices in active markets for identical assets or liabilities that the company has the ability to access.
	Level 2: Observable market based inputs or unobservable inputs that are corroborated by market data such as quoted prices, interest rates and yield curves.
	Level 3: Inputs are unobservable data points that are not corroborated by market data.
	The following table presents information about the company’s financial assets and liabilities measured at fair value on a recurring basis as of June 28, 2014:

				June 28,				Quoted Prices in Active Markets			Significant Other Observable Inputs			Significant Unobservable Inputs
	(In millions)				2014			(Level 1)			(Level 2)			(Level 3)

	Assets
		Cash equivalents			$	19.7		$	19.7		$	—		$	—
		Bank time deposits				21			21			—			—
		Investments in mutual funds, unit trusts and other similar instruments				10			10			—			—
		Insurance contracts				101.8			—			101.8			—
		Derivative contracts				3.9			—			3.9			—

			Total Assets		$	156.4		$	50.7		$	105.7		$	—

	Liabilities
		Derivative contracts			$	6.8		$	—		$	6.8		$	—
		Contingent consideration				32			—			—			32

			Total Liabilities		$	38.8		$	—		$	6.8		$	32


			The following table presents information about the company’s financial assets and liabilities measured at fair
	value on a recurring basis as of December 31, 2013:

				December 31,				Quoted Prices in Active Markets			Significant Other Observable Inputs			Significant Unobservable Inputs
	(In millions)				2013			(Level 1)			(Level 2)			(Level 3)

	Assets
		Cash equivalents			$	4,859.90		$	4,859.90		$	—		$	—
		Investments in mutual funds, unit trusts and other similar instruments				9.8			9.8			—			—
		Insurance contracts				74.5			—			74.5			—
		Auction rate securities				4.5			—			—			4.5
		Derivative contracts				3.8			—			3.8			—

			Total Assets		$	4,952.50		$	4,869.70		$	78.3		$	4.5

	Liabilities
		Derivative contracts			$	6.5		$	—		$	6.5		$	—
		Contingent consideration				5.1			—			—			5.1

			Total Liabilities		$	11.6		$	—		$	6.5		$	5.1


	The company determines the fair value of its insurance contracts by obtaining the cash surrender value of the contracts from the issuer. The fair value of derivative contracts is the estimated amount that the company would receive/pay upon liquidation of the contracts, taking into account the change in interest rates and currency exchange rates. The company determined the fair value of the auction rate securities by obtaining indications of value from brokers/dealers. The company determines the fair value of acquisition-related contingent consideration based on assessment of the probability that the company would be required to make such future payment. Changes to the fair value of contingent consideration are recorded in selling, general and administrative expense.
	In the second quarter of 2014, the company sold all of the auction rate securities and realized a net gain of $1.4 million. There was no significant activity within the auction rate securities during 2013. The following table provides a rollforward of the fair value, as determined by Level 3 inputs, of the contingent consideration.

				Three Months Ended						Six Months Ended
			June 28,			June 29,			June 28,			June 29,
	(In millions)			2014			2013			2014			2013

	Contingent Consideration
		Beginning Balance		$	33.1		$	20		$	5.1		$	20.1
		Acquisition			—			—			29.1			—
		Payments			-5			—			-6.1			—
		Change in fair value included in earnings			3.6			13.6			3.6			13.6
		Currency translation			0.3			0.1			0.3			—

	Ending Balance		$	32		$	33.7		$	32		$	33.7


The notional amounts of derivative contracts outstanding, consisting of currency exchange contracts and interest rate swaps, totaled $3.50 billion and $2.03 billion at June 28, 2014 and December 31, 2013, respectively.
While certain derivatives are subject to netting arrangements with counterparties, the company does not offset derivative assets and liabilities within the consolidated balance sheet. The following tables present the fair value of derivative instruments in the consolidated balance sheet and statement of income.

				Fair Value – Assets						Fair Value – Liabilities
			June 28,				December 31,		June 28,				December 31,
(In millions)				2014			2013			2014			2013

Derivatives Designated as Hedging Instruments
	Interest rate swaps (a)			$	—		$	—		$	1.4		$	5.2
Derivatives Not Designated as Hedging Instruments
	Currency exchange contracts (b)				3.9			3.8			5.4			1.3

(a)		The fair value of the interest rate swaps is included in the consolidated balance sheet under the caption other long-term liabilities.
(b)		The fair value of the currency exchange contracts is included in the consolidated balance sheet under the captions other current assets or other accrued expenses.


						Gain (Loss) Recognized
						Three Months Ended						Six Months Ended
					June 28,			June 29,			June 28,			June 29,
(In millions)							2014			2013			2014			2013

Derivatives Designated as Fair Value Hedges
	Interest rate swaps - effective portion					$	1		$	—		$	2.1		$	—
	Interest rate swaps - ineffective portion						1.1			—			1.8			—
Derivatives Not Designated as Fair Value Hedges
	Currency exchange contracts
		Included in cost of revenues				$	3.4		$	-0.5		$	4.2		$	0.5
		Included in other expense, net					-0.5			-1.9			0.2			14.8


Gains and losses recognized on currency exchange contracts and the effective portion of interest rate swaps are included in the consolidated statement of income together with the corresponding, offsetting losses and gains on the underlying hedged transactions. Gains and losses recognized on the ineffective portion of interest rate swaps is included in other expense, net in the accompanying statement of income.

Fair Value of Other Financial Instruments
The carrying value and fair value of the company’s notes receivable and debt obligations are as follows:

				28-Jun-14						31-Dec-13
				Carrying			Fair			Carrying			Fair
(In millions)				Value			Value			Value			Value

Notes Receivable				$	6.8		$	6.8		$	7.6		$	7.6

Debt Obligations:
	Senior notes			$	12,126.80		$	12,486.80		$	10,195.40		$	10,304.80
	Term loan				2,850.00			2,850.00			—			—
	Commercial paper				556.2			556.2			250			250
	Other				44.1			44.1			41.9			41.9

				$	15,577.10		$	15,937.10		$	10,487.30		$	10,596.70

		The fair value of debt obligations was determined based on quoted market prices and on borrowing rates
available to the company at the respective period ends which represent level 2 measurements.

Supplemental_Cash_Flow_Informa

Supplemental Cash Flow Information	6 Months Ended
Supplemental Cash Flow Information	Jun. 28, 2014
Supplemental Cash Flow Information [Abstract]	'
Supplemental Cash Flow Information [Text Block]	'
	Note 13. Supplemental Cash Flow Information

					Six Months Ended
				June 28,			June 29,
	(In millions)				2014			2013

	Non-cash Activities
		Fair value of assets of acquired businesses			$	19,649.10		$	—
		Cash paid for acquired businesses				-13,529.00			—

		Liabilities assumed of acquired businesses			$	6,120.10		$	—

		Fair value of available-for-sale investments contributed to defined
			benefit plans		$	—		$	27.1

		Declared but unpaid dividends			$	61.4		$	55.2

		Issuance of stock upon vesting of restricted stock units			$	76.8		$	53.5

Restructuring_and_Other_Costs_

Restructuring and Other Costs (Income), Net	6 Months Ended
Restructuring and Other Costs (Income), Net	Jun. 28, 2014
Restructuring And Other Costs, Net Disclosure	'
Restructuring and Other Costs, Net [Text Block]	'
	Note 14. Restructuring and Other Costs (Income), Net
	Restructuring and other costs (income) in the first six months of 2014 primarily included the gain on sale of the company’s sera and media, gene modulation and magnetic beads businesses to GE Healthcare, offset in part by sales of inventories revalued at the date of acquisition, cash compensation to monetize certain equity awards held by Life Technologies’ employees at the date of acquisition, acquisition transaction costs, severance obligations payable to former Life Technologies’ executives and employees, charges to conform the accounting policies of Life Technologies with the company’s accounting policies and, to a lesser extent, continuing charges for headcount reductions and facility consolidations in an effort to streamline operations, including the closure and consolidation of operations within several facilities in the U.S., Europe and Asia. In the first six months of 2014, severance actions associated with facility consolidations and cost reduction measures affected less than 1% of the company’s workforce.

	As of August 1, 2014, the company has identified restructuring actions that will result in additional charges of approximately $70 million, primarily in the remainder of 2014 which will be recorded when specified criteria are met, such as abandonment of facilities.

	Second Quarter of 2014
	During the second quarter of 2014, the company recorded net restructuring and other costs by segment as follows:

	(In millions)	Cost of Revenues			Selling, General and Administrative Expenses			Restructuring and Other Costs, Net			Total

	Life Sciences Solutions	$	155.8		$	12.3		$	47.4		$	215.5
	Analytical Instruments		—			1.1			3.1			4.2
	Specialty Diagnostics		0.2			1.5			4.9			6.6
	Laboratory Products and Services		0.1			—			4			4.1
	Corporate		—			—			1.5			1.5

		$	156.1		$	14.9		$	60.9		$	231.9


	The components of net restructuring and other costs by segment are as follows:
	Life Sciences Solutions
	The Life Sciences Solutions segment recorded $215.5 million of net restructuring and other charges in the second quarter of 2014. The segment recorded charges to cost of revenues of $155.8 million primarily for sales of inventories revalued at the date of acquisition; charges to selling, general and administrative expenses of $12.3 million primarily for transaction costs related to the acquisition of Life Technologies (Note 2); and $47.4 million of other restructuring costs, net, $39.7 million of which were cash costs. These costs, which were associated with headcount reductions and facility consolidations including the consolidation of various facilities in the U.S., consisted of $34.2 million of severance; $0.8 million of abandoned facility costs; and $4.7 million of other cash costs, including retention and outplacement costs. The segment also recorded a $10.9 million provision for losses on pre-acquisition litigation-related matters and a $3.2 million net gain on the sale of businesses.
	Analytical Instruments
	The Analytical Instruments segment recorded $4.2 million of net restructuring and other charges in the second quarter of 2014. The segment recorded charges to selling, general and administrative expenses of $1.1 million primarily for changes in estimates of contingent consideration for acquisitions and $3.1 million of other restructuring costs, net, $3.0 million of which were cash costs. These cash costs, which were associated with headcount reductions and facility consolidations including the consolidation and closure of several facilities in the U.S. and Europe, consisted of $1.4 million of severance; $0.8 million of abandoned facility costs; and $0.8 million of other cash costs related to facility consolidations.
	Specialty Diagnostics
	The Specialty Diagnostics segment recorded $6.6 million of net restructuring and other charges in the second quarter of 2014. The segment recorded charges to selling, general and administrative expenses of $1.5 million for changes in estimates of contingent consideration for an acquisition and $4.9 million of other restructuring costs, all of which were cash costs primarily associated with headcount reductions as well as the consolidation of a facility in Europe with existing facilities in Europe and China. The cash costs included $2.6 million of severance and the remainder principally for outplacement costs for severed employees and moving expenses associated with facility consolidations.
	Laboratory Products and Services
	The Laboratory Products and Services segment recorded $4.1 million of net restructuring and other charges in the second quarter of 2014. The segment recorded $3.9 million of cash costs which were associated with headcount reductions and facility consolidations to streamline operations, including $2.2 million of severance and $1.4 million of abandoned facility costs.
	Corporate
	During the second quarter of 2014, the company recorded $1.5 million of net restructuring and other charges primarily for a writedown to estimated disposal value of a fixed asset held for sale.

	First Six Months of 2014
	During the first six months of 2014, the company recorded net restructuring and other costs (income) as follows:

	(In millions)	Cost of Revenues			Selling, General and Administrative Expenses			Restructuring and Other Costs (Income), Net			Total

	Life Sciences Solutions	$	324.8		$	95.1		$	-540.7		$	-120.8
	Analytical Instruments		-0.8			1.1			4.3			4.6
	Specialty Diagnostics		0.4			1.5			7.7			9.6
	Laboratory Products and Services		0.2			—			5.2			5.4
	Corporate		—			—			2.2			2.2

		$	324.6		$	97.7		$	-521.3		$	-99


	The components of net restructuring and other costs (income) by segment are as follows:
	Life Sciences Solutions
	In the first six months of 2014, the Life Sciences Solutions segment recorded $120.8 million of other income, net of restructuring costs. The segment recorded a net gain of $760.4 million primarily from the divestiture of its sera and media, gene modulation and magnetic beads businesses (see Note 2). The gain was partially offset by restructuring and other charges including charges to cost of revenues of $324.8 million, consisting of $302.3 million of charges for sales of inventories revalued at the date of acquisition and $21.4 million of costs to conform the accounting policies of Life Technologies with the company’s accounting policies. The segment also recorded charges to selling, general and administrative expenses of $95.1 million, including $77.9 million of transaction costs related to the acquisition of Life Technologies (Note 2) and $16.2 million of costs to conform the accounting policies of Life Technologies with the company’s accounting policies. In addition, the segment recorded $208.5 million of cash restructuring costs, including $91.7 million for cash compensation to monetize certain equity awards held by Life Technologies’ employees at the date of acquisition with the remainder principally for severance obligations payable to former Life Technologies’ executives and employees as well as costs related to the consolidation of various facilities in the U.S. The segment also recorded a $10.9 million provision for losses on pre-acquisition litigation-related matters.
	Analytical Instruments
	In the first six months of 2014, the Analytical Instruments segment recorded $4.6 million of net restructuring and other charges. The segment recorded a net reduction in cost of revenues of $0.8 million; $1.1 million of charges to selling, general and administrative expenses for changes in estimates of contingent consideration; and $4.3 million of other costs, net. These other costs were primarily cash costs including abandoned facility costs and moving and other expenses associated with facility consolidations.
	Specialty Diagnostics
	In the first six months of 2014, the Specialty Diagnostics segment recorded $9.6 million of net restructuring and other charges, including $1.5 million of charges to selling, general and administrative expenses for changes in estimates of contingent consideration for an acquisition and $8.7 million of cash costs. The cash costs included $4.7 million for severance with the remainder principally for other costs associated with facility consolidations, including the consolidation of a facility in Europe with existing facilities in Europe and China. In addition, the segment recorded $1.0 million of income, net, primarily from a gain on the divestiture of a small business unit.
	Laboratory Products and Services
	In the first six months of 2014, the Laboratory Products and Services segment recorded $5.4 million of net restructuring and other charges, of which $5.0 million were cash costs primarily for severance and abandoned facility costs.
	Corporate
	In the first six months of 2014, the company recorded $2.2 million of net restructuring and other charges, including a writedown to estimated disposal value of a fixed asset held for sale and cash costs of $0.9 million for severance at its corporate operations.

	The following table summarizes the cash components of the company’s restructuring plans. The non-cash components and other amounts reported as restructuring and other costs, net, in the accompanying statement of income have been summarized in the notes to the tables. Accrued restructuring costs are included in other accrued expenses in the accompanying balance sheet.

						Abandonment
	(In millions)			Severance			of Excess Facilities			Other (a)			Total

	Pre-2013 Restructuring Plans
	Balance At December 31, 2013		$	6.6		$	8		$	0.3		$	14.9
	Costs incurred in 2014 (b)			1.1			1.9			—			3
	Reserves reversed			-1.3			—			-0.1			-1.4
	Payments			-2.4			-1.8			-0.1			-4.3
	Currency translation			-0.3			—			—			-0.3

	Balance At June 28, 2014		$	3.7		$	8.1		$	0.1		$	11.9

2013 Restructuring Plans
	Balance At December 31, 2013		$	22		$	1.4		$	2.2		$	25.6
	Costs incurred in 2014 (b)			4.9			1.7			5.3			11.9
	Reserves reversed			-2.4			-0.2			-0.1			-2.7
	Payments			-13.6			-1.7			-4.7			-20
	Currency translation			0.1			0.2			—			0.3

	Balance At June 28, 2014		$	11		$	1.4		$	2.7		$	15.1

2014 Restructuring Plans
	Costs incurred in 2014 (b)		$	111.9		$	1.2		$	84.2		$	197.3
	Payments			-82.6			-0.4			-80.5			-163.5
	Currency translation			0.1			—			—			0.1

	Balance At June 28, 2014		$	29.4		$	0.8		$	3.7		$	33.9


Other includes cash charges to monetize certain equity awards held by employees of Life Technologies at the date of acquisition, as well as employee retention costs which are accrued ratably over the period through which employees must work to qualify for a payment.
Excludes a $761.8 million net gain on the sale of businesses, principally the company’s sera and media, gene modulation and magnetic beads businesses; $19.6 million of cash compensation to monetize certain equity awards held by Life Technologies’ employees at the date of acquisition that was paid by Life Technologies prior to the acquisition; $10.9 million of provision for losses on pre-acquisition litigation-related matters of Life Technologies; and an aggregate of $1.9 million of non-cash charges, net.

The company expects to pay accrued restructuring costs as follows: severance, primarily through the first half of 2015; employee-retention obligations and other costs, primarily through 2014; and abandoned-facility payments, over lease terms expiring through 2020.

Discontinued_Operations

Discontinued Operations	6 Months Ended
Discontinued Operations	Jun. 28, 2014
Discontinued Operations [Abstract]	'
Discontinued Operations, Disclosure [Text Block]	'
	Note 15. Discontinued Operations
	In 2013, the company recorded an after-tax charge of $4.2 million for the estimated cost to raze certain abandoned facilities of discontinued operations prior to the planned sale of the related land.

Nature_of_Operations_and_Summa1

Nature of Operations and Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 28, 2014
Nature of Operations and Summary of Significant Accounting Policies [Abstract]	'
Use of Estimates [Policy Text Block]	'
	Use of Estimates
	The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. In addition, significant estimates were made in estimating future cash flows to assess potential impairment of assets and in determining the fair value of acquired intangible assets (Note 2) and the ultimate loss from abandoning leases at facilities being exited (Note 14). Actual results could differ from those estimates.

Acquisitions_and_Dispositions_

Acquisitions and Dispositions (Policies)	6 Months Ended
Acquisitions and Dispositions (Policies)	Jun. 28, 2014
Acquisitions and Dispositions Disclosure	'
Business Combinations Policy [Policy Text Block]	'
	The company’s acquisitions have historically been made at prices above the fair value of the acquired identifiable assets, resulting in goodwill, due to expectations of the synergies that will be realized by combining the businesses. These synergies include the elimination of redundant facilities, functions and staffing; use of the company’s existing commercial infrastructure to expand sales of the acquired businesses’ products; and use of the commercial infrastructure of the acquired businesses to cost-effectively expand sales of company products.
	Acquisitions have been accounted for using the purchase method of accounting, and the acquired companies’ results have been included in the accompanying financial statements from their respective dates of acquisition. Acquisition transaction costs are recorded in selling, general and administrative expenses as incurred.

Pension_and_Other_Postretireme1

Pension and Other Postretirement Benefit Plans (Policies)	6 Months Ended
Pension and Other Postretirement Benefit Plans (Policies)	Jun. 28, 2014
General Discussion of Pension and Other Postretirement Benefits [Abstract]	'
Pension and Other Postretirement Plans, Policy [Policy Text Block]	'
	Employees of a number of the company’s non-U.S. and certain U.S. subsidiaries participate in defined benefit pension plans covering substantially all full-time employees at those subsidiaries. Some of the plans are unfunded, as permitted under the plans and applicable laws. The company also maintains postretirement healthcare programs at several acquired businesses where certain employees are eligible to participate. The costs of the postretirement healthcare programs are funded on a self-insured and insured-premium basis.

Nature_of_Operations_and_Summa2

Nature of Operations and Summary of Significant Accounting Policies (Tables)	6 Months Ended
	Jun. 28, 2014
Nature of Operations and Summary of Significant Accounting Policies [Abstract]	'
Warranty Obligations [Table Text Block]	'
	Warranty Obligations
	Product warranties are included in other accrued expenses in the accompanying balance sheet. The changes in the carrying amount of warranty obligations are as follows:

					Six Months Ended
				June 28,			June 29,
	(In millions)				2014			2013

	Beginning Balance				$	49.8		$	48.7
		Provision charged to income				38.2			34.8
		Usage				-39.2			-37.1
		Acquisitions				7.2			—
		Adjustments to previously provided warranties, net				0.9			0.3
		Other, net				—			-0.5

	Ending Balance				$	56.9		$	46.2
Inventories [Table Text Block]	'
	Inventories
	The components of inventories are as follows:

				June 28,				December 31,
	(In millions)					2014		2013

	Raw Materials				$	461.3		$	347.4
	Work in Process					217.2			157.7
	Finished Goods					1,255.30			989.4

	Inventories				$	1,933.80		$	1,494.50

Property, Plant and Equipment [Table Text Block]	'
	Property, Plant and Equipment
	Property, plant and equipment consists of the following:

				June 28,				December 31,
	(In millions)					2014		2013

	Land				$	294.9		$	212.2
	Buildings and Improvements					1,025.40			821
	Machinery, Equipment and Leasehold Improvements					2,569.20			2,047.90

	Property, Plant and Equipment, at Cost					3,889.50			3,081.10
	Less: Accumulated Depreciation and Amortization					1,417.50			1,313.70

	Property, Plant and Equipment, at Cost, Net				$	2,472.00		$	1,767.40

Finite-Lived Acquisition-related Intangible Assets [Table Text Block]	'
	Acquisition-related Intangible Assets
	Acquisition-related intangible assets are as follows:

			28-Jun-14								31-Dec-13
					Accumulated								Accumulated
	(In millions)		Gross			Amortization			Net		Gross			Amortization		Net

	Definite Lived		$	18,715.20		$	-4,937.80		$	13,777.40	$	10,121.80		$	-4,388.20	$	5,733.60
	Indefinite Lived			1,844.20			—			1,844.20		1,337.70			—		1,337.70

	Acquisition-related Intangible Assets		$	20,559.40		$	-4,937.80		$	15,621.60	$	11,459.50		$	-4,388.20	$	7,071.30

Indefinite-lived Acquisition-related Intangible Assets [Table Text Block]	'
	Acquisition-related Intangible Assets
	Acquisition-related intangible assets are as follows:

			28-Jun-14								31-Dec-13
					Accumulated								Accumulated
	(In millions)		Gross			Amortization			Net		Gross			Amortization		Net

	Definite Lived		$	18,715.20		$	-4,937.80		$	13,777.40	$	10,121.80		$	-4,388.20	$	5,733.60
	Indefinite Lived			1,844.20			—			1,844.20		1,337.70			—		1,337.70

	Acquisition-related Intangible Assets		$	20,559.40		$	-4,937.80		$	15,621.60	$	11,459.50		$	-4,388.20	$	7,071.30

Acquisitions_and_Dispositions_1

Acquisitions and Dispositions (Tables)	6 Months Ended
Acquisitions and Dispositions (Tables)	Jun. 28, 2014
Acquisitions and Dispositions Disclosure	'
Schedule of Business Acquisitions, by Acquisition [Table Text Block]	'
			The components of the purchase price and net assets acquired for 2014 acquisitions are as follows:

	(In millions)				Life Technologies		Other			Total

	Purchase Price
		Cash paid			$	13,487.30	$	41.7		$	13,529.00
		Debt assumed				2,279.70		—			2,279.70
		Purchase price payable				—		4			4
		Cash acquired				-463		-11.5			-474.5

					$	15,304.00	$	34.2		$	15,338.20

	Net Assets Acquired
		Current assets			$	1,768.10	$	18.4		$	1,786.50
		Property, plant and equipment				752.3		1.1			753.4
		Definite-lived intangible assets:
			Customer relationships			5,864.00		5.5			5,869.50
			Product technology			2,624.60		5.5			2,630.10
			Tradenames and other			240.6		—			240.6
		Indefinite-lived intangible assets:
			Tradenames			448.2		—			448.2
			In-process research and development			58.4		—			58.4
		Goodwill				7,123.50		12.5			7,136.00
		Other assets				251.8		0.1			251.9
		Liabilities assumed				-3,827.50		-8.9			-3,836.40

					$	15,304.00	$	34.2		$	15,338.20

Business Acquisition, Pro Forma Information [Table Text Block]	'
	Had the acquisition of Life Technologies been completed as of the beginning of 2013, the company’s pro forma results for 2014 and 2013 would have been as follows:

							Three Months Ended			Six Months Ended
							June 29,		June 28,			June 29,
	(In millions except per share amounts)						2013			2014		2013

	Revenues						$	4,153.60		$	8,501.50	$	8,268.60

	Income from Continuing Operations						$	319.8		$	1,114.90	$	326.2

	Net Income						$	319.6		$	1,114.90	$	321.4

	Earnings per Share from Continuing Operations:
		Basic					$	0.81		$	2.8	$	0.83
		Diluted					$	0.8		$	2.77	$	0.82

	Earnings per Share:
		Basic					$	0.81		$	2.8	$	0.82
		Diluted					$	0.8		$	2.77	$	0.81


	Pro forma results include non-recurring pro forma adjustments that were directly attributable to the business combination, as follows:

	Pre tax charge to selling, general and administrative expenses of $208.2 million in the six months ended June 29, 2013, for acquisition-related transaction costs incurred by the company and Life Technologies;
	Pre tax charge to cost of revenues of $55.4 million and $301.4 million in the three and six months ended June 29, 2013, for the sale of Life Technologies inventories revalued at the date of acquisition;
	Pre tax charge of $91.7 million in the six months ended June 29, 2013, for monetizing equity awards held by Life Technologies’ employees at the date of acquisition;
	Pre tax charge of $37.6 million in the six months ended June 29, 2013, to conform the accounting policies of Life Technologies with the company's accounting policies; and
	Pre tax reduction of revenues of $5.2 million, $4.7 million and $16.8 million in the three months ended June 29, 2013 and the six months ended June 28, 2014 and June 29, 2013, respectively, for revaluing Life Technologies’ deferred revenue obligations to fair value.

Schedule of Disposal Groups, Including Discontinued Operations, Income Statement, Balance Sheet and Additional Disclosures [Table Text Block]	'
	The assets and liabilities of the Cole-Parmer business were as follows at June 28, 2014:

		June 28,
	(In millions)		2014

	Current Assets		$	39.5
	Long-term Assets			400.3
	Current Liabilities			15.5
	Long-term Liabilities			84.1


	The assets and liabilities of the businesses sold in March 2014 were as follows at December 31, 2013:

		December 31,
	(In millions)		2013

	Current Assets		$	74.3
	Long-term Assets			229.3
	Current Liabilities			6.4
	Long-term Liabilities			22

Business_Segment_Information_T

Business Segment Information (Tables)	6 Months Ended
Business Segment Information (Tables)	Jun. 28, 2014
Business Segments	'
Schedule of Segment Reporting Information, by Segment [Table Text Block]	'
	Business Segment Information

					Three Months Ended						Six Months Ended
				June 28,			June 29,			June 28,			June 29,
	(In millions)				2014			2013			2014			2013

	Revenues
		Life Sciences Solutions			$	1,103.10		$	181		$	1,938.60		$	353.6
		Analytical Instruments				793.4			761			1,563.30			1,501.10
		Specialty Diagnostics				855.1			793.6			1,668.80			1,599.20
		Laboratory Products and Services				1,699.40			1,595.00			3,289.90			3,151.30
		Eliminations				-129.1			-90.5			-235.2			-173.6

			Consolidated revenues			4,321.90			3,240.10			8,225.40			6,431.60

	Segment Income
		Life Sciences Solutions (a)				299.1			43.5			543.7			84.5
		Analytical Instruments (a)				130.4			125.3			261.3			245.8
		Specialty Diagnostics (a)				236.4			216.3			457.4			439.2
		Laboratory Products and Services (a)				257.7			238.7			491.7			469.4

			Subtotal reportable segments (a)			923.6			623.8			1,754.10			1,238.90

		Cost of revenues charges				-156.1			-13.1			-324.6			-26.3
		Selling, general and administrative charges, net				-14.9			-22.6			-97.7			-23.9
		Restructuring and other (costs) income, net				-60.9			-21.5			521.3			-43
		Amortization of acquisition-related intangible assets				-343.6			-191.2			-629.5			-383.2

			Consolidated operating income			348.1			375.4			1,223.60			762.5
		Other expense, net (b)				-111.6			-95.4			-212.7			-139.6

		Income from continuing operations before income taxes			$	236.5		$	280		$	1,010.90		$	622.9

	Depreciation
		Life Sciences Solutions			$	36.3		$	4.1		$	60.3		$	8.2
		Analytical Instruments				9.2			9.8			19.6			20
		Specialty Diagnostics				19.2			18.1			38			36.6
		Laboratory Products and Services				26.5			26			53			52.2

			Consolidated depreciation		$	91.2		$	58		$	170.9		$	117

	(a)	Represents operating income before certain charges to cost of revenues and selling, general and administrative expenses; restructuring and other costs, net; and amortization of acquisition-related intangibles.

	(b)	The company does not allocate other expense, net to its segments.

Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]	'
	Business Segment Information

					Three Months Ended						Six Months Ended
				June 28,			June 29,			June 28,			June 29,
	(In millions)				2014			2013			2014			2013

	Revenues
		Life Sciences Solutions			$	1,103.10		$	181		$	1,938.60		$	353.6
		Analytical Instruments				793.4			761			1,563.30			1,501.10
		Specialty Diagnostics				855.1			793.6			1,668.80			1,599.20
		Laboratory Products and Services				1,699.40			1,595.00			3,289.90			3,151.30
		Eliminations				-129.1			-90.5			-235.2			-173.6

			Consolidated revenues			4,321.90			3,240.10			8,225.40			6,431.60

	Segment Income
		Life Sciences Solutions (a)				299.1			43.5			543.7			84.5
		Analytical Instruments (a)				130.4			125.3			261.3			245.8
		Specialty Diagnostics (a)				236.4			216.3			457.4			439.2
		Laboratory Products and Services (a)				257.7			238.7			491.7			469.4

			Subtotal reportable segments (a)			923.6			623.8			1,754.10			1,238.90

		Cost of revenues charges				-156.1			-13.1			-324.6			-26.3
		Selling, general and administrative charges, net				-14.9			-22.6			-97.7			-23.9
		Restructuring and other (costs) income, net				-60.9			-21.5			521.3			-43
		Amortization of acquisition-related intangible assets				-343.6			-191.2			-629.5			-383.2

			Consolidated operating income			348.1			375.4			1,223.60			762.5
		Other expense, net (b)				-111.6			-95.4			-212.7			-139.6

		Income from continuing operations before income taxes			$	236.5		$	280		$	1,010.90		$	622.9

	Depreciation
		Life Sciences Solutions			$	36.3		$	4.1		$	60.3		$	8.2
		Analytical Instruments				9.2			9.8			19.6			20
		Specialty Diagnostics				19.2			18.1			38			36.6
		Laboratory Products and Services				26.5			26			53			52.2

			Consolidated depreciation		$	91.2		$	58		$	170.9		$	117

	(a)	Represents operating income before certain charges to cost of revenues and selling, general and administrative expenses; restructuring and other costs, net; and amortization of acquisition-related intangibles.

	(b)	The company does not allocate other expense, net to its segments.

Other_Expense_Net_Tables

Other Expense, Net (Tables)	6 Months Ended
Other Expense, Net (Tables)	Jun. 28, 2014
Other Expense, Net Disclosure	'
Schedule of Other Nonoperating Income (Expense) [Table Text Block]	'
			Three Months Ended						Six Months Ended
		June 28,			June 29,			June 28,			June 29,
	(In millions)		2014			2013			2014			2013

	Interest Income		$	16		$	7.1		$	27.9		$	14.3
	Interest Expense			-129.1			-64.4			-246.9			-128.8
	Other Items, Net			1.5			-38.1			6.3			-25.1

	Other Expense, Net		$	-111.6		$	-95.4		$	-212.7		$	-139.6

Stockbased_Compensation_Expens1

Stockbased Compensation Expense (Tables)	6 Months Ended
Stockbased Compensation Expense (Tables)	Jun. 28, 2014
Stock-based Compensation Expense Disclosure [Abstract]	'
Schedule of Compensation Cost for Share-based Payment Arrangements, Allocation of Share-based Compensation Costs by Plan [Table Text Block]	'
		The components of stock-based compensation expense are as follows:

				Three Months Ended						Six Months Ended
			June 28,			June 29,			June 28,			June 29,
	(In millions)			2014			2013			2014			2013

	Stock Option Awards			$	11.7		$	10.6		$	22.4		$	20.2
	Restricted Unit Awards				19.1			12.7			33.6			23.5

	Total Stock-based Compensation Expense			$	30.8		$	23.3		$	56		$	43.7

Pensions_and_Other_Postretirem

Pensions and Other Postretirement Benefit Plans (Tables)	6 Months Ended
Pensions and Other Postretirement Benefit Plans (Tables)	Jun. 28, 2014
Defined Benefit Pension Plans and Defined Benefit Postretirement Plans Disclosure [Abstract]	'
Schedule of Net Benefit Costs [Table Text Block]	'
	Net periodic benefit costs for the company’s defined benefit pension plans include the following components:

			Three Months Ended						Six Months Ended
		June 28,			June 29,			June 28,			June 29,
	(In millions)		2014			2013			2014			2013

	Service Cost - Benefits Earned		$	5		$	5.8		$	9.6		$	9.4
	Interest Cost on Benefit Obligation			23.5			11.9			43.6			23.9
	Expected Return on Plan Assets			-25.1			-13.2			-46.2			-26.4
	Amortization of Net Loss			2.1			2.9			4			5.7
	Amortization of Prior Service Benefit			-0.1			-0.1			-0.1			-0.2
	Special Termination Benefits			—			0.4			—			0.5

	Net Periodic Benefit Cost		$	5.4		$	7.7		$	10.9		$	12.9

Income_Taxes_Tables

Income Taxes (Tables)	6 Months Ended
Income Taxes (Tables)	Jun. 28, 2014
Income Taxes Disclosure [Abstract]	'
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	'
			The provision for income taxes in the accompanying statement of income differs from the provision calculated
	by applying the statutory federal income tax rate of 35% to income from continuing operations before provision for
	income taxes due to the following:

					Six Months Ended
				June 28,			June 29,
	(In millions)				2014			2013

	Provision for Income Taxes at Statutory Rate				$	353.8		$	218

	Increases (Decreases) Resulting From:
		Foreign rate differential				-60.8			-119.8
		Impact of change in tax laws and apportionment on deferred taxes				-25.9			-1.8
		Foreign and research and development tax credits				-59.4			-79.5
		Manufacturing deduction				-8.9			-13.4
		State income taxes, net of federal tax				23.1			-1.8
		Nondeductible expenses				3.3			3.3
		Provision of tax reserves, net				25.3			—
		Basis difference on disposal of businesses				-61.9			—
		Other, net				0.7			-0.5

					$	189.3		$	4.5

Earnings_per_Share_Tables

Earnings per Share (Tables)	6 Months Ended
Earnings per Share (Tables)	Jun. 28, 2014
Earnings per Share	'
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	'
				Three Months Ended						Six Months Ended
			June 28,			June 29,			June 28,			June 29,
	(In millions except per share amounts)			2014			2013			2014			2013

	Income from Continuing Operations			$	278.5		$	277.6		$	821.6		$	618.4
	Loss from Discontinued Operations				—			-0.2			—			-0.6
	Loss on Disposal of Discontinued Operations, Net				—			—			—			-4.2

	Net Income			$	278.5		$	277.4		$	821.6		$	613.6

	Basic Weighted Average Shares				399.4			360			396.3			359
	Plus Effect of:
		Equity forward arrangement			—			—			0.3			—
		Stock options and restricted units			3.7			3.5			4.1			3.6

	Diluted Weighted Average Shares				403.1			363.5			400.7			362.6

	Basic Earnings per Share:
		Continuing operations		$	0.7		$	0.77		$	2.07		$	1.72
		Discontinued operations			—			—			—			-0.01

				$	0.7		$	0.77		$	2.07		$	1.71

	Diluted Earnings per Share:
		Continuing operations		$	0.69		$	0.76		$	2.05		$	1.71
		Discontinued operations			—			—			—			-0.01

				$	0.69		$	0.76		$	2.05		$	1.69

Debt_and_Other_Financing_Arran1

Debt and Other Financing Arrangements (Tables)	6 Months Ended
Debt and Other Financing Arrangements (Tables)	Jun. 28, 2014
Debt And Other Financing Arrangements Disclosure [Abstract]	'
Schedule of Debt [Table Text Block]	'
			Effective
			Interest Rate at	June 28,			December 31,
	(Dollars in millions)		28-Jun-14		2014		2013

	Commercial Paper		0.55%		$	556.2	$	250
	Term Loan		1.62%			2,850.00		—
	2.05% Senior Notes, Due 2014					—		300
	3.25% Senior Notes, Due 2014		1.57%			400		400
	4.40% Senior Notes, Due 2015		0.75%			500		—
	3.20% Senior Notes, Due 2015		1.58%			450		450
	5.00% Senior Notes, Due 2015		5.13%			250		250
	3.50% Senior Notes, Due 2016		1.05%			400		—
	3.20% Senior Notes, Due 2016		3.21%			900		900
	2.25% Senior Notes, Due 2016		2.29%			1,000.00		1,000.00
	1.30% Senior Notes, Due 2017		0.91%			900		900
	1.85% Senior Notes, Due 2018		1.85%			500		500
	2.40% Senior Notes, Due 2019		2.44%			900		900
	6.00% Senior Notes, Due 2020		2.98%			750		—
	4.70% Senior Notes, Due 2020		4.70%			300		300
	5.00% Senior Notes, Due 2021		3.25%			400		—
	4.50% Senior Notes, Due 2021		4.58%			1,000.00		1,000.00
	3.60% Senior Notes, Due 2021		4.29%			1,100.00		1,100.00
	3.15% Senior Notes, Due 2023		3.21%			800		800
	4.15% Senior Notes, Due 2024		4.07%			1,000.00		1,000.00
	5.30% Senior Notes, Due 2044		5.30%			400		400
	Other					44.1		41.9

	Total Borrowings at Par Value					15,400.30		10,491.90
		Fair Value Hedge Accounting Adjustments				7.3		12.9
		Unamortized Premium (Discount), Net				169.5		-17.5

	Total Borrowings at Carrying Value					15,577.10		10,487.30
		Less: Short-term Obligations and Current Maturities				3,075.10		987.7

	Long-term Obligations				$	12,502.00	$	9,499.60

Comprehensive_Income_and_Share1

Comprehensive Income and Shareholders Equity (Tables)	6 Months Ended
Comprehensive Income and Shareholders Equity (Tables)	Jun. 28, 2014
Comprehensive Income and Shareholders Equity Disclosure [Abstract]	'
Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]	'
	(In millions)				Currency Translation Adjustment		Unrealized Gains (Losses) on Available-for-Sale Investments			Unrealized Gains (Losses) on Hedging Instruments			Pension and Other Postretirement Benefit Liability Adjustment		Total

	Balance at December 31, 2013				$	112	$	1.3		$	-23.9		$	-166.6	$	-77.2
		Other comprehensive income (loss) before reclassifications				-36.4		1.8			—			-2.6		-37.2
		Amounts reclassified from accumulated other comprehensive items				—		-1.4			1.5			2.6		2.7

			Net other comprehensive items			-36.4		0.4			1.5			—		-34.5

	Balance at June 28, 2014				$	75.6	$	1.7		$	-22.4		$	-166.6	$	-111.7

Reclassification out of Accumulated Other Comprehensive Income [Table Text Block]	'
	The amounts reclassified out of accumulated other comprehensive items are as follows:

										Six Months Ended
						Affected Line Item in the			June 28,			June 29,
	(In millions)					Statement of Income				2014			2013

	Amounts Reclassified From Accumulated Other Comprehensive Items
		Unrealized gains and losses on available-for-sale investments:
			Realized gain on sale or transfer of available-for- sale investments			Other Expense, Net				$	-1.4		$	-10.5
			Tax provision			Provision for Income Taxes					—			2.5

											-1.4			-8

		Unrealized gains and losses on hedging instruments:
			Realized loss on interest rate swaps and locks			Other Expense, Net					2.4			2.6
			Tax benefit			Provision for Income Taxes					-0.9			-1

											1.5			1.6

		Pension and other postretirement benefit liability adjustment:
			Amortization of actuarial losses			Net Periodic Benefit Cost -					4			5.8
			Amortization of prior service benefit			see Note 6 for details					-0.2			-0.2

				Total before tax							3.8			5.6
			Tax benefit			Provision for Income Taxes					-1.2			-1.8

											2.6			3.8

				Total reclassifications						$	2.7		$	-2.6

Fair_Value_Measurements_and_Fa1

Fair Value Measurements and Fair Value of Financial Instruments (Tables)	6 Months Ended
	Jun. 28, 2014
Fair Value Measurements and Fair Value of Financial Instruments Disclosure	'
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]	'
	The following table presents information about the company’s financial assets and liabilities measured at fair value on a recurring basis as of June 28, 2014:

				June 28,				Quoted Prices in Active Markets			Significant Other Observable Inputs			Significant Unobservable Inputs
	(In millions)				2014			(Level 1)			(Level 2)			(Level 3)

	Assets
		Cash equivalents			$	19.7		$	19.7		$	—		$	—
		Bank time deposits				21			21			—			—
		Investments in mutual funds, unit trusts and other similar instruments				10			10			—			—
		Insurance contracts				101.8			—			101.8			—
		Derivative contracts				3.9			—			3.9			—

			Total Assets		$	156.4		$	50.7		$	105.7		$	—

	Liabilities
		Derivative contracts			$	6.8		$	—		$	6.8		$	—
		Contingent consideration				32			—			—			32

			Total Liabilities		$	38.8		$	—		$	6.8		$	32


			The following table presents information about the company’s financial assets and liabilities measured at fair
	value on a recurring basis as of December 31, 2013:

				December 31,				Quoted Prices in Active Markets			Significant Other Observable Inputs			Significant Unobservable Inputs
	(In millions)				2013			(Level 1)			(Level 2)			(Level 3)

	Assets
		Cash equivalents			$	4,859.90		$	4,859.90		$	—		$	—
		Investments in mutual funds, unit trusts and other similar instruments				9.8			9.8			—			—
		Insurance contracts				74.5			—			74.5			—
		Auction rate securities				4.5			—			—			4.5
		Derivative contracts				3.8			—			3.8			—

			Total Assets		$	4,952.50		$	4,869.70		$	78.3		$	4.5

	Liabilities
		Derivative contracts			$	6.5		$	—		$	6.5		$	—
		Contingent consideration				5.1			—			—			5.1

			Total Liabilities		$	11.6		$	—		$	6.5		$	5.1

Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	'
	The following table provides a rollforward of the fair value, as determined by Level 3 inputs, of the contingent consideration.

				Three Months Ended						Six Months Ended
			June 28,			June 29,			June 28,			June 29,
	(In millions)			2014			2013			2014			2013

	Contingent Consideration
		Beginning Balance		$	33.1		$	20		$	5.1		$	20.1
		Acquisition			—			—			29.1			—
		Payments			-5			—			-6.1			—
		Change in fair value included in earnings			3.6			13.6			3.6			13.6
		Currency translation			0.3			0.1			0.3			—

		Ending Balance		$	32		$	33.7		$	32		$	33.7

Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]	'
					Fair Value – Assets						Fair Value – Liabilities
				June 28,				December 31,		June 28,				December 31,
	(In millions)				2014			2013			2014			2013

	Derivatives Designated as Hedging Instruments
		Interest rate swaps (a)			$	—		$	—		$	1.4		$	5.2
	Derivatives Not Designated as Hedging Instruments
		Currency exchange contracts (b)				3.9			3.8			5.4			1.3

	(a)		The fair value of the interest rate swaps is included in the consolidated balance sheet under the caption other long-term liabilities.
	(b)		The fair value of the currency exchange contracts is included in the consolidated balance sheet under the captions other current assets or other accrued expenses.

Schedule of Derivative Instruments, Gain (Loss) in Statement of Financial Performance [Table Text Block]	'
							Gain (Loss) Recognized
							Three Months Ended						Six Months Ended
						June 28,			June 29,			June 28,			June 29,
	(In millions)							2014			2013			2014			2013

	Derivatives Designated as Fair Value Hedges
		Interest rate swaps - effective portion					$	1		$	—		$	2.1		$	—
		Interest rate swaps - ineffective portion						1.1			—			1.8			—
	Derivatives Not Designated as Fair Value Hedges
		Currency exchange contracts
			Included in cost of revenues				$	3.4		$	-0.5		$	4.2		$	0.5
			Included in other expense, net					-0.5			-1.9			0.2			14.8

Fair Value, by Balance Sheet Grouping [Table Text Block]	'
	Fair Value of Other Financial Instruments
	The carrying value and fair value of the company’s notes receivable and debt obligations are as follows:

					28-Jun-14						31-Dec-13
					Carrying			Fair			Carrying			Fair
	(In millions)				Value			Value			Value			Value

	Notes Receivable				$	6.8		$	6.8		$	7.6		$	7.6

	Debt Obligations:
		Senior notes			$	12,126.80		$	12,486.80		$	10,195.40		$	10,304.80
		Term loan				2,850.00			2,850.00			—			—
		Commercial paper				556.2			556.2			250			250
		Other				44.1			44.1			41.9			41.9

					$	15,577.10		$	15,937.10		$	10,487.30		$	10,596.70

			The fair value of debt obligations was determined based on quoted market prices and on borrowing rates
	available to the company at the respective period ends which represent level 2 measurements.

Schedule of Carrying Values and Estimated Fair Values of Debt Instruments [Table Text Block]	'
	Fair Value of Other Financial Instruments
	The carrying value and fair value of the company’s notes receivable and debt obligations are as follows:

					28-Jun-14						31-Dec-13
					Carrying			Fair			Carrying			Fair
	(In millions)				Value			Value			Value			Value

	Notes Receivable				$	6.8		$	6.8		$	7.6		$	7.6

	Debt Obligations:
		Senior notes			$	12,126.80		$	12,486.80		$	10,195.40		$	10,304.80
		Term loan				2,850.00			2,850.00			—			—
		Commercial paper				556.2			556.2			250			250
		Other				44.1			44.1			41.9			41.9

					$	15,577.10		$	15,937.10		$	10,487.30		$	10,596.70

			The fair value of debt obligations was determined based on quoted market prices and on borrowing rates
	available to the company at the respective period ends which represent level 2 measurements.

Supplemental_Cash_Flow_Informa1

Supplemental Cash Flow Information (Tables)	6 Months Ended
Supplemental Cash Flow Information (Tables)	Jun. 28, 2014
Supplemental Cash Flow Information [Abstract]	'
Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]	'
					Six Months Ended
				June 28,			June 29,
	(In millions)				2014			2013

	Non-cash Activities
		Fair value of assets of acquired businesses			$	19,649.10		$	—
		Cash paid for acquired businesses				-13,529.00			—

		Liabilities assumed of acquired businesses			$	6,120.10		$	—

		Fair value of available-for-sale investments contributed to defined
			benefit plans		$	—		$	27.1

		Declared but unpaid dividends			$	61.4		$	55.2

		Issuance of stock upon vesting of restricted stock units			$	76.8		$	53.5

Restructuring_and_Other_Costs_1

Restructuring and Other Costs (Income), Net (Tables)	6 Months Ended
Restructuring and Other Costs (Income), Net (Tables)	Jun. 28, 2014
Restructuring And Other Costs, Net Disclosure	'
Schedule of Restructuring and Related Costs [Table Text Block]	'
	Second Quarter of 2014
	During the second quarter of 2014, the company recorded net restructuring and other costs by segment as follows:

	(In millions)		Cost of Revenues			Selling, General and Administrative Expenses			Restructuring and Other Costs, Net			Total

	Life Sciences Solutions		$	155.8		$	12.3		$	47.4		$	215.5
	Analytical Instruments			—			1.1			3.1			4.2
	Specialty Diagnostics			0.2			1.5			4.9			6.6
	Laboratory Products and Services			0.1			—			4			4.1
	Corporate			—			—			1.5			1.5

			$	156.1		$	14.9		$	60.9		$	231.9


	First Six Months of 2014
	During the first six months of 2014, the company recorded net restructuring and other costs (income) as follows:

	(In millions)		Cost of Revenues			Selling, General and Administrative Expenses			Restructuring and Other Costs (Income), Net			Total

	Life Sciences Solutions		$	324.8		$	95.1		$	-540.7		$	-120.8
	Analytical Instruments			-0.8			1.1			4.3			4.6
	Specialty Diagnostics			0.4			1.5			7.7			9.6
	Laboratory Products and Services			0.2			—			5.2			5.4
	Corporate			—			—			2.2			2.2

			$	324.6		$	97.7		$	-521.3		$	-99

Schedule of Restructuring Reserve by Type of Cost [Table Text Block]	'
	The following table summarizes the cash components of the company’s restructuring plans. The non-cash components and other amounts reported as restructuring and other costs, net, in the accompanying statement of income have been summarized in the notes to the tables. Accrued restructuring costs are included in other accrued expenses in the accompanying balance sheet.

							Abandonment
	(In millions)				Severance			of Excess Facilities			Other (a)			Total

	Pre-2013 Restructuring Plans
		Balance At December 31, 2013			$	6.6		$	8		$	0.3		$	14.9
		Costs incurred in 2014 (b)				1.1			1.9			—			3
		Reserves reversed				-1.3			—			-0.1			-1.4
		Payments				-2.4			-1.8			-0.1			-4.3
		Currency translation				-0.3			—			—			-0.3

		Balance At June 28, 2014			$	3.7		$	8.1		$	0.1		$	11.9

	2013 Restructuring Plans
		Balance At December 31, 2013			$	22		$	1.4		$	2.2		$	25.6
		Costs incurred in 2014 (b)				4.9			1.7			5.3			11.9
		Reserves reversed				-2.4			-0.2			-0.1			-2.7
		Payments				-13.6			-1.7			-4.7			-20
		Currency translation				0.1			0.2			—			0.3

		Balance At June 28, 2014			$	11		$	1.4		$	2.7		$	15.1

	2014 Restructuring Plans
		Costs incurred in 2014 (b)			$	111.9		$	1.2		$	84.2		$	197.3
		Payments				-82.6			-0.4			-80.5			-163.5
		Currency translation				0.1			—			—			0.1

		Balance At June 28, 2014			$	29.4		$	0.8		$	3.7		$	33.9


	Other includes cash charges to monetize certain equity awards held by employees of Life Technologies at the date of acquisition, as well as employee retention costs which are accrued ratably over the period through which employees must work to qualify for a payment.
	Excludes a $761.8 million net gain on the sale of businesses, principally the company’s sera and media, gene modulation and magnetic beads businesses; $19.6 million of cash compensation to monetize certain equity awards held by Life Technologies’ employees at the date of acquisition that was paid by Life Technologies prior to the acquisition; $10.9 million of provision for losses on pre-acquisition litigation-related matters of Life Technologies; and an aggregate of $1.9 million of non-cash charges, net.

	The company expects to pay accrued restructuring costs as follows: severance, primarily through the first half of 2015; employee-retention obligations and other costs, primarily through 2014; and abandoned-facility payments, over lease terms expiring through 2020.

Warranty_Obligations_Details

Warranty Obligations (Details) (USD $)	6 Months Ended
In Millions, unless otherwise specified	Jun. 28, 2014	Jun. 29, 2013
Warranty Obligation [Roll Forward]	'	'
Beginning Balance	$49.80	$48.70
Provision charged to income	38.2	34.8
Usage	-39.2	-37.1
Acquisitions	7.2	0
Adjustments to previously provided warranties, net	0.9	0.3
Other, net	0	-0.5
Ending Balance	$56.90	$46.20

Inventories_Details

Inventories (Details) (USD $)	Jun. 28, 2014	Dec. 31, 2013
In Millions, unless otherwise specified	Jun. 28, 2014	Dec. 31, 2013
Inventories [Abstract]	'	'
Raw Materials	$461.30	$347.40
Work in Process	217.2	157.7
Finished Goods	1,255.30	989.4
Inventories	$1,933.80	$1,494.50

Property_Plant_and_Equipment_D

Property, Plant and Equipment (Details) (USD $)	3 Months Ended		6 Months Ended
In Millions, unless otherwise specified	Jun. 28, 2014	Jun. 29, 2013	Jun. 28, 2014	Jun. 29, 2013	Dec. 31, 2013
Property, Plant and Equipment [Line Items]	'	'	'	'	'
Property, Plant and Equipment, at Cost	$3,889.50	'	$3,889.50	'	$3,081.10
Less: Accumulated depreciation and amortization	1,417.50	'	1,417.50	'	1,313.70
Property, Plant and Equipment, at Cost, Net	2,472	'	2,472	'	1,767.40
Depreciation and amortization expense of property, plant and equipment	91.2	58	170.9	117	'
Land [Member]	'	'	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'	'	'
Property, Plant and Equipment, at Cost	294.9	'	294.9	'	212.2
Building and Improvements [Member]	'	'	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'	'	'
Property, Plant and Equipment, at Cost	1,025.40	'	1,025.40	'	821
Machinery, Equipment and Leasehold Improvements [Member]	'	'	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'	'	'
Property, Plant and Equipment, at Cost	$2,569.20	'	$2,569.20	'	$2,047.90

Acquisitionrelated_Intangible_

Acquisition-related Intangible Assets (Details) (USD $)	Jun. 28, 2014	Dec. 31, 2013
In Millions, unless otherwise specified	Jun. 28, 2014	Dec. 31, 2013
Definite-Lived Intangible Assets [Line Items]	'	'
Definite-Lived Intangible Assets, Gross	$18,715.20	$10,121.80
Accumulated Amortization	-4,937.80	-4,388.20
Definite-Lived Intangible Assets, Net	13,777.40	5,733.60
Indefinite-lived Intangible Assets by Major Class [Line Items]	'	'
Indefinite-Lived Intangible Assets	1,844.20	1,337.70
Acquisition-related Intangible Assets, Gross	20,559.40	11,459.50
Acquisition-related Intangible Assets, net of Accumulated Amortization	$15,621.60	$7,071.30

Completed_Acquisitions_Purchas

Completed Acquisitions Purchase Price (Details) (USD $)

6 Months Ended

0 Months Ended

6 Months Ended

In Millions, unless otherwise specified

Jun. 28, 2014

Feb. 03, 2014

Jun. 28, 2014

Tradenames [Member]

In-process Research and Development [Member]

Customer Relationships [Member]

Product Technology [Member]

Tradenames and other [Member]

Life Technologies Corporation [Member]

Other Acquisitions [Member]

Tradenames [Member]

In-process Research and Development [Member]

Customer Relationships [Member]

Product Technology [Member]

Tradenames and other [Member]

Tradenames [Member]

In-process Research and Development [Member]

Customer Relationships [Member]

Product Technology [Member]

Tradenames and other [Member]

Purchase Price

Cash Paid

$13,529

$13,487.30

$41.70

Debt Assumed

2,279.70

Purchase Price Payable

Cash acquired

-474.5

-463

-11.5

Total Purchase Price

15,338.20

15,304

34.2

Net Assets Acquired

Current assets

1,786.50

1,768.10

18.4

Property, plant and equipment

753.4

752.3

1.1

Definite-lived intangible assets

5,869.50

2,630.10

240.6

5,864

2,624.60

240.6

5.5

Indefinite-lived intangible assets

448.2

58.4

448.2

58.4

Goodwill

7,136

7,123.50

12.5

Other assets

251.9

251.8

0.1

Liabilities assumed

-3,836.40

-3,827.50

-8.9

Total Purchase Price

$15,338.20

$15,304

$34.20

Acquired Finite-lived Intangible Asset, Weighted Average Useful Life (in years)

'14 years

'16 years

'11 years

'9 years

Completed_Acquisitions_Other_I

Completed Acquisitions Other Information (Details) (USD $)	6 Months Ended		12 Months Ended
	Jun. 28, 2014	Jun. 29, 2013	Dec. 31, 2013	Feb. 03, 2014
	Jun. 28, 2014	Jun. 29, 2013	Life Technologies Corporation [Member]	Life Technologies Corporation [Member]
Other Information	'	'	'	'
Purchase Price Paid	$13,054,500,000	$4,700,000	'	'
Revenue Reported by Acquired Entity	'	'	3,870,000,000	'
Goodwill, Expected Tax Deductible Amount	'	'	'	$0	[1]

[1]	Substantially none of the goodwill is tax deductible

Acquisition_Pro_Forma_Results_

Acquisition Pro Forma Results (Details) (USD $)

3 Months Ended

6 Months Ended

3 Months Ended

6 Months Ended

3 Months Ended

6 Months Ended

3 Months Ended

6 Months Ended

Jun. 29, 2013

Jun. 28, 2014

Jun. 29, 2013

Jun. 28, 2014

Jun. 29, 2013

Jun. 28, 2014

Jun. 29, 2013

Life Technologies Corporation [Member]

Non-recurring Pro Forma Adjustments, Deferred Revenue

Non-recurring Pro Forma Adjustments, Fair Value Adjustment to Inventories

Non-recurring Pro Forma Adjustments, Transaction Costs

Non-recurring Pro Forma Adjustments, Monetized Equity Awards

Non-recurring Pro Forma Adjustments, Conform Accounting Policies

Business Acquisition [Line Items]

Revenue of Acquiree(s) since date of acquisition

$960,000,000

$1,620,000,000

Business Acquisition, Pro Forma Information [Abstract]

Revenues

4,153,600,000

8,501,500,000

8,268,600,000

-5,200,000

-4,700,000

-16,800,000

Income from Continuing Operations

319,800,000

1,114,900,000

326,200,000

-55,400,000

-301,400,000

-208,200,000

-91,700,000

-37,600,000

Net Income

$319,600,000

$1,114,900,000

$321,400,000

Earnings per Share from Continuing Operations:

Basic (in dollars per share)

$0.81

$2.80

$0.83

Diluted (in dollars per share)

$0.80

$2.77

$0.82

Earnings per Share:

Basic (in dollars per share)

$0.81

$2.80

$0.82

Diluted (in dollars per share)

$0.80

$2.77

$0.81

Dispositions_Details

Dispositions (Details) (USD $)	6 Months Ended		0 Months Ended	3 Months Ended	12 Months Ended	6 Months Ended	12 Months Ended
	Jun. 28, 2014	Jun. 29, 2013	Mar. 21, 2014	Mar. 21, 2014	Dec. 31, 2013	Jun. 28, 2014	Dec. 31, 2013	Jul. 17, 2014
	Jun. 28, 2014	Jun. 29, 2013	Sera & Media, Gene Modulation and Magnetic Beads Businesses [Member]	Sera & Media, Gene Modulation and Magnetic Beads Businesses [Member]	Sera & Media, Gene Modulation and Magnetic Beads Businesses [Member]	Cole-Parmer specialty channel business [Member]	Cole-Parmer specialty channel business [Member]	Cole-Parmer specialty channel business [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]	'	'	'	'	'	'	'	'
Consideration, per agreement to sell business	'	'	'	'	'	'	'	$480,000,000
Proceeds from sale of businesses, net of cash divested	1,048,700,000	0	1,050,000,000	'	'	'	'	'
Proceeds from sale of businesses, net of cash divested and income tax payments	'	'	800,000,000	'	'	'	'	'
Gain (Loss) on Divestiture of Businesses	761,800,000	0	761,000,000	'	'	'	'	'
Revenues	'	'	'	61,000,000	250,000,000	119,000,000	232,000,000	'
Operating Income	'	'	'	12,000,000	64,000,000	23,000,000	43,000,000	'
Current Assets	'	'	'	'	74,300,000	39,500,000	'	'
Long-term Assets	'	'	'	'	229,300,000	400,300,000	'	'
Current Liabilities	'	'	'	'	6,400,000	15,500,000	'	'
Long-term Liabilities	'	'	'	'	$22,000,000	$84,100,000	'	'

Business_Segment_Information_D

Business Segment Information (Details) (USD $)	3 Months Ended				6 Months Ended
In Millions, unless otherwise specified	Jun. 28, 2014		Jun. 29, 2013		Jun. 28, 2014		Jun. 29, 2013		Dec. 31, 2013
	Jun. 28, 2014		Jun. 29, 2013		Segment		Jun. 29, 2013		Dec. 31, 2013
Business Segments	'		'		'		'		'
Number of Reportable Segments	'		'		4		'		'
Segment Reporting Information [Line Items]	'		'		'		'		'
Revenues	$4,321.90		$3,240.10		$8,225.40		$6,431.60		'
Cost of revenues charges	-156.1		'		-324.6		'		'
Selling, general and administrative charges, net	-14.9		'		-97.7		'		'
Restructuring and other income (costs), net	-60.9		-21.5		521.3		-43		'
Operating Income	348.1		375.4		1,223.60		762.5		'
Other expense, net	-111.6		-95.4		-212.7		-139.6		'
Income from Continuing Operations Before Income Taxes	236.5		280		1,010.90		622.9		'
Depreciation	91.2		58		170.9		117		'
Total Assets	44,313.40		'		44,313.40		'		31,863.40
Capital Expenditures	'		'		180.2		131.6		'
Life Sciences Solutions [Member]	'		'		'		'		'
Segment Reporting Information [Line Items]	'		'		'		'		'
Cost of revenues charges	-155.8		'		-324.8		'		'
Selling, general and administrative charges, net	-12.3		'		-95.1		'		'
Restructuring and other income (costs), net	-47.4		'		540.7		'		'
Analytical Instruments [Member]	'		'		'		'		'
Segment Reporting Information [Line Items]	'		'		'		'		'
Cost of revenues charges	0		'		0.8		'		'
Selling, general and administrative charges, net	-1.1		'		-1.1		'		'
Restructuring and other income (costs), net	-3.1		'		-4.3		'		'
Specialty Diagnostics [Member]	'		'		'		'		'
Segment Reporting Information [Line Items]	'		'		'		'		'
Cost of revenues charges	-0.2		'		-0.4		'		'
Selling, general and administrative charges, net	-1.5		'		-1.5		'		'
Restructuring and other income (costs), net	-4.9		'		-7.7		'		'
Laboratory Products and Services [Member]	'		'		'		'		'
Segment Reporting Information [Line Items]	'		'		'		'		'
Cost of revenues charges	-0.1		'		-0.2		'		'
Selling, general and administrative charges, net	0		'		'		'		'
Restructuring and other income (costs), net	-4		'		-5.2		'		'
Total Reportable Segments [Member]	'		'		'		'		'
Segment Reporting Information [Line Items]	'		'		'		'		'
Operating Income	923.6	[1]	623.8	[1]	1,754.10	[1]	1,238.90	[1]	'
Total Reportable Segments [Member] \| Life Sciences Solutions [Member]	'		'		'		'		'
Segment Reporting Information [Line Items]	'		'		'		'		'
Revenues	1,103.10		181		1,938.60		353.6		'
Operating Income	299.1	[1]	43.5	[1]	543.7	[1]	84.5	[1]	'
Depreciation	36.3		4.1		60.3		8.2		'
Total Reportable Segments [Member] \| Analytical Instruments [Member]	'		'		'		'		'
Segment Reporting Information [Line Items]	'		'		'		'		'
Revenues	793.4		761		1,563.30		1,501.10		'
Operating Income	130.4	[1]	125.3	[1]	261.3	[1]	245.8	[1]	'
Depreciation	9.2		9.8		19.6		20		'
Total Reportable Segments [Member] \| Specialty Diagnostics [Member]	'		'		'		'		'
Segment Reporting Information [Line Items]	'		'		'		'		'
Revenues	855.1		793.6		1,668.80		1,599.20		'
Operating Income	236.4	[1]	216.3	[1]	457.4	[1]	439.2	[1]	'
Depreciation	19.2		18.1		38		36.6		'
Total Reportable Segments [Member] \| Laboratory Products and Services [Member]	'		'		'		'		'
Segment Reporting Information [Line Items]	'		'		'		'		'
Revenues	1,699.40		1,595		3,289.90		3,151.30		'
Operating Income	257.7	[1]	238.7	[1]	491.7	[1]	469.4	[1]	'
Depreciation	26.5		26		53		52.2		'
Intersegment Eliminations [Member]	'		'		'		'		'
Segment Reporting Information [Line Items]	'		'		'		'		'
Revenues	-129.1		-90.5		-235.2		-173.6		'
Segment Reconciling Items [Member]	'		'		'		'		'
Segment Reporting Information [Line Items]	'		'		'		'		'
Cost of revenues charges	-156.1		-13.1		-324.6		-26.3		'
Selling, general and administrative charges, net	-14.9		-22.6		-97.7		-23.9		'
Restructuring and other income (costs), net	-60.9		-21.5		521.3		-43		'
Amortization of acquisition-related intangible assets	($343.60)		($191.20)		($629.50)		($383.20)		'

[1]	Represents operating income before certain charges to cost of revenues and selling, general and administrative expenses; restructuring and other costs, net; and amortization of acquisition-related intangibles.

Other_Expense_Net_Details

Other Expense, Net (Details) (USD $)	3 Months Ended		6 Months Ended
In Millions, unless otherwise specified	Jun. 28, 2014	Jun. 29, 2013	Jun. 28, 2014	Jun. 29, 2013
Other Expense, Net Disclosure	'	'	'	'
Interest Income	$16	$7.10	$27.90	$14.30
Interest Expense	-129.1	-64.4	-246.9	-128.8
Other Items, Net	1.5	-38.1	6.3	-25.1
Other Expense, Net	-111.6	-95.4	-212.7	-139.6
Gain on sale of investment accounted for under cost method	'	'	'	2
Fees Associated with Short-term Financing Commitments	'	'	'	41
Fair value of available-for-sale investments contributed to defined benefit plans	'	'	'	27.1
Available-for-sale Securities, Gross Realized Gains	'	'	'	11
Gain on Sale of Investments	'	'	$5	'

Stockbased_Compensation_Expens2

Stockbased Compensation Expense (Details) (USD $)	3 Months Ended		6 Months Ended
In Millions, unless otherwise specified	Jun. 28, 2014	Jun. 29, 2013	Jun. 28, 2014	Jun. 29, 2013
Employee Service Share-based Compensation, Aggregate Disclosures [Abstract]	'	'	'	'
Stock Option Awards	$11.70	$10.60	$22.40	$20.20
Restricted Unit Awards	19.1	12.7	33.6	23.5
Stock-based Compensation Expense	30.8	23.3	56	43.7
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Compensation Expense, Cash-in-Lieu of Pre-acquisition Equity Awards	10	'	17.1	'
Stock Options [Member]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Unrecognized Compensation Costs On Nonvested Awards	104	'	104	'
Unrecognized Compensation Costs On Nonvested Awards, Weighted Average Period Of Recognition	'	'	'2 years 9 months	'
Stock Options [Member] \| Maximum [Member]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Unrecognized Compensation Costs On Nonvested Awards, Period Of Recognition	'	'	'4 years	'
Restricted Units [Member]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Unrecognized Compensation Costs On Nonvested Awards	$142	'	$142	'
Unrecognized Compensation Costs On Nonvested Awards, Weighted Average Period Of Recognition	'	'	'2 years 6 months	'
Restricted Units [Member] \| Maximum [Member]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Unrecognized Compensation Costs On Nonvested Awards, Period Of Recognition	'	'	'3 years	'

Stockbased_Compensation_Stock_

Stockbased Compensation, Stock Option Disclosures (Details) (USD $)	6 Months Ended
In Millions, unless otherwise specified	Jun. 28, 2014	Jun. 29, 2013
Stock-based Compensation Expense Disclosure [Abstract]	'	'
Tax benefit related to employees' and directors' stock plans	$55.50	$28.40
Options Outstanding [Roll Forward]	'	'
Granted	2.5	'

Stockbased_Compensation_Restri

Stockbased Compensation, Restricted Units Disclosures (Details)	6 Months Ended
In Millions, unless otherwise specified	Jun. 28, 2014
Unvested Restricted Units [Roll Forward]	'
Granted	1

Pensions_Net_Benefit_Cost_Deta

Pensions Net Benefit Cost (Details) (Pension Plans, Defined Benefit [Member], USD $)	3 Months Ended		6 Months Ended
In Millions, unless otherwise specified	Jun. 28, 2014	Jun. 29, 2013	Jun. 28, 2014	Jun. 29, 2013
Pension Plans, Defined Benefit [Member]	'	'	'	'
Components of Net Benefit Cost (Income)	'	'	'	'
Service Cost-Benefits Earned	$5	$5.80	$9.60	$9.40
Interest Cost on Benefit Obligation	23.5	11.9	43.6	23.9
Expected Return on Plan Assets	-25.1	-13.2	-46.2	-26.4
Amortization of Actuarial Net Loss	2.1	2.9	4	5.7
Amortization of Prior Service Benefit	-0.1	-0.1	-0.1	-0.2
Special Termination Benefits	0	0.4	0	0.5
Net Periodic Benefit Cost	$5.40	$7.70	$10.90	$12.90

Income_Taxes_Rate_Reconciliati

Income Taxes Rate Reconciliation (Details) (USD $)	3 Months Ended		6 Months Ended
In Millions, unless otherwise specified	Jun. 28, 2014	Jun. 29, 2013	Jun. 28, 2014	Jun. 29, 2013
Income Tax Expense (Benefit), Continuing Operations, Income Tax Reconciliation [Abstract]	'	'	'	'
Federal Statutory Income Tax Rate	'	'	35.00%	35.00%
Provision for Income Taxes at Statutory Rate	'	'	$353.80	$218
Foreign rate differential	'	'	-60.8	-119.8
Impact of change in tax laws and apportionment on deferred taxes	'	'	-25.9	-1.8
Foreign and research and development tax credits	'	'	-59.4	-79.5
Manufacturing deduction	'	'	-8.9	-13.4
State income taxes, net of federal tax	'	'	23.1	-1.8
Nondeductible expenses	'	'	3.3	3.3
Provision (reversal) of tax reserves, net	'	'	25.3	0
Basis difference on disposal of businesses	'	'	-61.9	0
Other, net	'	'	0.7	-0.5
Provision for Income Taxes	($42)	$2.40	$189.30	$4.50

Income_Taxes_Unrecognized_Tax_

Income Taxes - Unrecognized Tax Benefits (Details) (USD $)	6 Months Ended
In Millions, unless otherwise specified	Jun. 28, 2014
Reconciliation Of Unrecognized Tax Benefits [Roll Forward]	'
Balance at beginning of year	$134.20
Additions due to acquisitions	100.3
Additions for tax positions of current year	54.4
Reductions for tax positions of prior years	-29.1
Balance at end of year	$259.80

EPS_Calculation_Details

EPS Calculation (Details) (USD $)	3 Months Ended		6 Months Ended
In Millions, except Per Share data, unless otherwise specified	Jun. 28, 2014	Jun. 29, 2013	Jun. 28, 2014	Jun. 29, 2013
Earnings per Share	'	'	'	'
Income from Continuing Operations	$278.50	$277.60	$821.60	$618.40
Loss from Discontinued Operations	0	-0.2	0	-0.6
Loss on Disposal of Discontinued Operations, Net	0	0	0	-4.2
Net Income	$278.50	$277.40	$821.60	$613.60
Basic Weighted Average Shares	399.4	360	396.3	359
Effect of Equity Forward Arrangement	0	0	0.3	0
Effect of Stock Options and Restricted Units	3.7	3.5	4.1	3.6
Diluted Weighted Average Shares	403.1	363.5	400.7	362.6
Basic Earnings per Share:	'	'	'	'
Continuing operations (in dollars per share)	$0.70	$0.77	$2.07	$1.72
Discontinued operations (in dollars per share)	$0	$0	$0	($0.01)
Earnings Per Share, Basic (in dollars per share)	$0.70	$0.77	$2.07	$1.71
Diluted Earnings per Share:	'	'	'	'
Continuing operations (in dollars per share)	$0.69	$0.76	$2.05	$1.71
Discontinued operations (in dollars per share)	$0	$0	$0	($0.01)
Earnings Per Share, Diluted (in dollars per share)	$0.69	$0.76	$2.05	$1.69
Stock Options [Member]	'	'	'	'
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]	'	'	'	'
Antidilutive Stock Options Excluded From Computation Of Earnings Per Share	2.5	1.8	2.4	1.8

Debt_Outstanding_Debt_Details

Debt Outstanding Debt (Details) (USD $)	6 Months Ended
In Millions, unless otherwise specified	Jun. 28, 2014	Feb. 03, 2014	Dec. 31, 2013
Debt Instrument [Line Items]	'	'	'
Principal Outstanding	$15,400.30	'	$10,491.90
Fair Value Hedge Accounting Adjustments	7.3	'	12.9
Unamortized Premium (Discount), Net	169.5	'	-17.5
Debt Obligations - Carrying Value	15,577.10	'	10,487.30
Less: Short-term obligations and current maturities of long-term obligations	3,075.10	'	987.7
Long-term Obligations	12,502	'	9,499.60
Commercial Paper [Member]	'	'	'
Debt Instrument [Line Items]	'	'	'
Effective Interest Rate	0.55%	'	'
Principal Outstanding	556.2	'	250
Debt Obligations - Carrying Value	556.2	'	250
Term Loan	'	'	'
Debt Instrument [Line Items]	'	'	'
Debt Instrument, Maturity Year	'2017	'	'
Effective Interest Rate	1.62%	'	'
Principal Outstanding	2,850	'	0
Debt Obligations - Carrying Value	2,850	'	0
Debt, Covenant, Maximum Consolidated Total Leverage Ratio of Debt to EBITDA until August 2014	5.5	'	'
Debt, Covenant, Maximum Consolidated Total Leverage Ratio Of Debt To EBITDA by August 2015	3.5	'	'
Debt, Covenant, Minimum Consolidated Interest Coverage Ratio	3	'	'
Senior Notes [Member]	'	'	'
Debt Instrument [Line Items]	'	'	'
Debt Obligations - Carrying Value	12,126.80	'	10,195.40
Debt Instrument, Frequency of Periodic Payment	'Interest on each of the senior notes is payable semi-annually.	'	'
Debt Instrument, Call Feature	'Each of the notes may be redeemed at any time at a redemption price of 100% of the principal amount plus a specified make-whole premium plus accrued interest	'	'
Business Combination, Fair Value of Long-term Debt in Excess of Par Value	'	207	'
Senior Notes [Member] \| 2.05% Senior Notes Due 2014 [Member]	'	'	'
Debt Instrument [Line Items]	'	'	'
Stated Interest Rate	2.05%	'	'
Debt Instrument, Maturity Year	'2014	'	'
Principal Outstanding	0	'	300
Senior Notes [Member] \| 3.25% Senior Notes Due 2014 [Member]	'	'	'
Debt Instrument [Line Items]	'	'	'
Stated Interest Rate	3.25%	'	'
Debt Instrument, Maturity Year	'2014	'	'
Effective Interest Rate	1.57%	'	'
Principal Outstanding	400	'	400
Senior Notes [Member] \| 4.40% Senior Notes, Due 2015 [Member]	'	'	'
Debt Instrument [Line Items]	'	'	'
Stated Interest Rate	4.40%	'	'
Debt Instrument, Maturity Year	'2015	'	'
Effective Interest Rate	0.75%	'	'
Principal Outstanding	500	'	0
Senior Notes [Member] \| 3.20% Senior Notes due 2015 [Member]	'	'	'
Debt Instrument [Line Items]	'	'	'
Stated Interest Rate	3.20%	'	'
Debt Instrument, Maturity Year	'2015	'	'
Effective Interest Rate	1.58%	'	'
Principal Outstanding	450	'	450
Senior Notes [Member] \| 5.00% Senior Notes due 2015 [Member]	'	'	'
Debt Instrument [Line Items]	'	'	'
Stated Interest Rate	5.00%	'	'
Debt Instrument, Maturity Year	'2015	'	'
Effective Interest Rate	5.13%	'	'
Principal Outstanding	250	'	250
Senior Notes [Member] \| 3.50% Senior Notes, Due 2016 [Member]	'	'	'
Debt Instrument [Line Items]	'	'	'
Stated Interest Rate	3.50%	'	'
Debt Instrument, Maturity Year	'2016	'	'
Effective Interest Rate	1.05%	'	'
Principal Outstanding	400	'	0
Senior Notes [Member] \| 3.20% Senior Notes Due 2016 [Member]	'	'	'
Debt Instrument [Line Items]	'	'	'
Stated Interest Rate	3.20%	'	'
Debt Instrument, Maturity Year	'2016	'	'
Effective Interest Rate	3.21%	'	'
Principal Outstanding	900	'	900
Senior Notes [Member] \| 2.25% Senior Notes Due 2016 [Member]	'	'	'
Debt Instrument [Line Items]	'	'	'
Stated Interest Rate	2.25%	'	'
Debt Instrument, Maturity Year	'2016	'	'
Effective Interest Rate	2.29%	'	'
Principal Outstanding	1,000	'	1,000
Senior Notes [Member] \| 1.30% Senior Notes Due 2017 [Member]	'	'	'
Debt Instrument [Line Items]	'	'	'
Stated Interest Rate	1.30%	'	'
Debt Instrument, Maturity Year	'2017	'	'
Effective Interest Rate	0.91%	'	'
Principal Outstanding	900	'	900
Senior Notes [Member] \| 1.85% Senior Notes Due 2018 [Member]	'	'	'
Debt Instrument [Line Items]	'	'	'
Stated Interest Rate	1.85%	'	'
Debt Instrument, Maturity Year	'2018	'	'
Effective Interest Rate	1.85%	'	'
Principal Outstanding	500	'	500
Senior Notes [Member] \| 2.40% Senior Notes Due 2019 [Member]	'	'	'
Debt Instrument [Line Items]	'	'	'
Stated Interest Rate	2.40%	'	'
Debt Instrument, Maturity Year	'2019	'	'
Effective Interest Rate	2.44%	'	'
Principal Outstanding	900	'	900
Senior Notes [Member] \| 6.00% Senior Notes, Due 2020 [Member]	'	'	'
Debt Instrument [Line Items]	'	'	'
Stated Interest Rate	6.00%	'	'
Debt Instrument, Maturity Year	'2020	'	'
Effective Interest Rate	2.98%	'	'
Principal Outstanding	750	'	0
Senior Notes [Member] \| 4.70% Senior Notes due 2020 [Member]	'	'	'
Debt Instrument [Line Items]	'	'	'
Stated Interest Rate	4.70%	'	'
Debt Instrument, Maturity Year	'2020	'	'
Effective Interest Rate	4.70%	'	'
Principal Outstanding	300	'	300
Senior Notes [Member] \| 5.00% Senior Notes, Due 2021 [Member]	'	'	'
Debt Instrument [Line Items]	'	'	'
Stated Interest Rate	5.00%	'	'
Debt Instrument, Maturity Year	'2021	'	'
Effective Interest Rate	3.25%	'	'
Principal Outstanding	400	'	0
Senior Notes [Member] \| 4.50% Senior Notes Due 2021 [Member]	'	'	'
Debt Instrument [Line Items]	'	'	'
Stated Interest Rate	4.50%	'	'
Debt Instrument, Maturity Year	'2021	'	'
Effective Interest Rate	4.58%	'	'
Principal Outstanding	1,000	'	1,000
Senior Notes [Member] \| 3.60% Senior Notes Due 2021 [Member]	'	'	'
Debt Instrument [Line Items]	'	'	'
Stated Interest Rate	3.60%	'	'
Debt Instrument, Maturity Year	'2021	'	'
Effective Interest Rate	4.29%	'	'
Principal Outstanding	1,100	'	1,100
Senior Notes [Member] \| 3.15% Senior Notes Due 2023 [Member]	'	'	'
Debt Instrument [Line Items]	'	'	'
Stated Interest Rate	3.15%	'	'
Debt Instrument, Maturity Year	'2023	'	'
Effective Interest Rate	3.21%	'	'
Principal Outstanding	800	'	800
Senior Notes [Member] \| 4.15% Senior Notes Due 2024 [Member]	'	'	'
Debt Instrument [Line Items]	'	'	'
Stated Interest Rate	4.15%	'	'
Debt Instrument, Maturity Year	'2024	'	'
Effective Interest Rate	4.07%	'	'
Principal Outstanding	1,000	'	1,000
Senior Notes [Member] \| 5.30% Senior Notes Due 2044 [Member]	'	'	'
Debt Instrument [Line Items]	'	'	'
Stated Interest Rate	5.30%	'	'
Debt Instrument, Maturity Year	'2044	'	'
Effective Interest Rate	5.30%	'	'
Principal Outstanding	400	'	400
Other Debt [Member]	'	'	'
Debt Instrument [Line Items]	'	'	'
Principal Outstanding	44.1	'	41.9
Debt Obligations - Carrying Value	$44.10	'	$41.90

Debt_Future_Repayments_Details

Debt Future Repayments (Details) (USD $)	Jun. 28, 2014	Dec. 31, 2013
Maturities of Long-term Debt [Abstract]	'	'
Total Repayments of Principal	$15,400,300,000	$10,491,900,000
Term Loan	'	'
Maturities of Long-term Debt [Abstract]	'	'
Remainder of 2014	375,000,000	'
2015	1,000,000,000	'
2016	1,000,000,000	'
Total Repayments of Principal	$2,850,000,000	$0

Debt_Shortterm_Financing_Detai

Debt Short-term Financing (Details) (USD $)	6 Months Ended
Debt Short-term Financing (Details) (USD $)	Jun. 28, 2014
Revolving Credit Facility [Member]	'
Line of Credit Facility [Line Items]	'
Line of Credit Facility, Maximum Borrowing Capacity	$1,500,000,000
Line of Credit Facility, Expiration Date	31-Jul-18
Debt, Covenant, Maximum Consolidated Total Leverage Ratio of Debt to EBITDA until August 2014	5.5
Debt, Covenant, Maximum Consolidated Total Leverage Ratio Of Debt To EBITDA by August 2015	3.5
Debt, Covenant, Minimum Consolidated Interest Coverage Ratio	3
Letters of Credit Outstanding, Amount	58,000,000
Line of Credit Facility, Amount Outstanding	$0
U.S. Commercial Paper Program [Member]	'
Short-term Financing [Line Items]	'
Short-term Borrowings, Weighted Average Interest Rate	0.55%
Maximum Period to Maturity Allowed Under Program	'397 days
Short-term Debt, Period to Maturity	'37 days

Interest_Rate_Swap_Arrangement

Interest Rate Swap Arrangements (Details) (USD $)	3 Months Ended		6 Months Ended
In Millions, unless otherwise specified	Jun. 28, 2014	Jun. 29, 2013	Jun. 28, 2014	Jun. 29, 2013	Dec. 31, 2013
Debt Instrument [Line Items]	'	'	'	'	'
Notional Amount Of Derivatives	$3,500	'	$3,500	'	$2,030
Change in fair value of cash flow hedges, net of tax	0	6.7	0	6.7	'
Senior Notes 1.30% Due 2017 [Member] \| Interest Rate Swaps [Member]	'	'	'	'	'
Debt Instrument [Line Items]	'	'	'	'	'
Notional Amount Of Derivatives	$900	'	$900	'	'
Interest Rate Swap, Spread above One-month LIBOR	0.66%	'	0.66%	'	'
Interest Rate Swap, Variable Rate at Period End	0.81%	'	0.81%	'	'
Fixed Interest Rate	1.30%	'	1.30%	'	'

Commitments_and_Contingencies_

Commitments and Contingencies (Details) (Life Technologies Corporation [Member], USD $)	0 Months Ended
In Millions, unless otherwise specified	Feb. 03, 2014
Enzo Biochem, Enzo Life Sciences and Yale Univ [Member]	'
Loss Contingency [Abstract]	'
Loss Contingency Accrued	$60.90
Loss Contingencies [Line Items]	'
Damages Awarded	48.5
Prejudgment Interest Awarded	12.4
Loss Contingency Accrued	60.9
Promega Corp and Max-Plank-Gesellschaft [Member]	'
Loss Contingency [Abstract]	'
Loss Contingency Accrued	52
Loss Contingencies [Line Items]	'
Damages Awarded	52
Loss Contingency Accrued	$52

Comprehensive_Income_and_Share2

Comprehensive Income and Shareholders' Equity (Details) (USD $)

3 Months Ended

6 Months Ended

1 Months Ended

6 Months Ended

0 Months Ended

6 Months Ended

In Millions, except Share data, unless otherwise specified

Jun. 28, 2014

Jun. 29, 2013

Jun. 28, 2014

Jun. 29, 2013

Dec. 31, 2013

Jan. 31, 2014

Jun. 28, 2014

Feb. 03, 2014

Jun. 28, 2014

Jun. 29, 2013

Jun. 28, 2014

Jun. 29, 2013

Jun. 28, 2014

Jun. 29, 2013

Jun. 28, 2014

Jun. 29, 2013

Equity Forward Agreements [Member]

Subscription Agreement [Member]

Reclassification out of Accumulated Other Comprehensive Income [Member]

Currency Translation Adjustment [Member]

Unrealized Gains (Losses) on Available-for-Sale Investments [Member]

Unrealized Gains (Losses) on Hedging Instruments [Member]

Pension and Other Postretirement Benefit Liability Adjustment [Member]

Reclassification out of Accumulated Other Comprehensive Income [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Accumulated Other Comprehensive Items, Beginning Balance

($77.20)

$112

$1.30

($23.90)

($166.60)

Other comprehensive income (loss) before reclassifications

-37.2

-36.4

1.8

-2.6

Amounts reclassified from accumulated other comprehensive items

2.7

-1.4

1.5

2.6

Total other comprehensive items

-48.9

-126.7

-34.5

-305.6

-36.4

0.4

1.5

Accumulated Other Comprehensive Items, Ending Balance

-111.7

75.6

1.7

-22.4

-166.6

Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]

Other Expense, Net

111.6

95.4

212.7

139.6

-1.4

-10.5

2.4

2.6

Net Periodic Benefit Cost - Amortization of Actuarial Losses

5.8

Net Periodic Benefit Cost - Amortization of Prior Service Benefit

-0.2

Total Before Tax

-236.5

-280

-1,010.90

-622.9

3.8

5.6

Provision for Income Taxes

-42

2.4

189.3

4.5

2.5

-0.9

-1

-1.2

-1.8

Net of Tax

($278.50)

($277.40)

($821.60)

($613.60)

$2.70

($2.60)

($1.40)

($8)

$1.50

$1.60

$2.60

$3.80

Class of Stock Disclosures [Abstract]

Preferred Stock, $100 Par Value - Shares Authorized (in shares)

50,000

Preferred Stock, $100 Par Value - Par Value (in dollars per share)

$100

Forward Contract Indexed to Issuer's Equity [Line Items]

Forward Contract Indexed to Issuer's Equity, Current Forward Rate Per Share

$82.53

$94.85

Forward Contract Indexed To Issuer's Equity, Settlement Date

31-Jan-14

Issuance of shares (in shares)

29,600,000

5,300,000

Fair_Value_Measurements_Assets

Fair Value Measurements, Assets and Liabilities (Details) (Fair Value, Measurements, Recurring [Member], USD $)	Jun. 28, 2014	Dec. 31, 2013
In Millions, unless otherwise specified	Jun. 28, 2014	Dec. 31, 2013
Assets	'	'
Cash equivalents	$19.70	$4,859.90
Bank time deposits	21	'
Investments in mutual funds, unit trusts and other similar instruments	10	9.8
Insurance contracts	101.8	74.5
Auction rate securities	'	4.5
Derivative contracts	3.9	3.8
Total Assets	156.4	4,952.50
Liabilities	'	'
Derivative contracts	6.8	6.5
Contingent consideration	32	5.1
Total Liabilities	38.8	11.6
Quoted Prices in Active Markets (Level I) [Member]	'	'
Assets	'	'
Cash equivalents	19.7	4,859.90
Bank time deposits	21	'
Investments in mutual funds, unit trusts and other similar instruments	10	9.8
Total Assets	50.7	4,869.70
Significant Other Observable Inputs (Level 2) [Member]	'	'
Assets	'	'
Insurance contracts	101.8	74.5
Derivative contracts	3.9	3.8
Total Assets	105.7	78.3
Liabilities	'	'
Derivative contracts	6.8	6.5
Total Liabilities	6.8	6.5
Significant Unobservable Inputs (Level 3) [Member]	'	'
Assets	'	'
Auction rate securities	'	4.5
Total Assets	'	4.5
Liabilities	'	'
Contingent consideration	32	5.1
Total Liabilities	$32	$5.10

Fair_Value_Measurements_Availa

Fair Value Measurements, Available-for-sale Securities (Details) (USD $)	6 Months Ended
In Millions, unless otherwise specified	Jun. 29, 2013
Available-for-sale Securities [Abstract]	'
Fair value of available-for-sale investments contributed to defined benefit plans	$27.10
Available-for-sale Securities, Gross Realized Gains	$11

Fair_Value_Measurements_Level_

Fair Value Measurements, Level 3 Reconciliation (Details) (USD $)	3 Months Ended		6 Months Ended
In Millions, unless otherwise specified	Jun. 28, 2014	Jun. 29, 2013	Jun. 28, 2014	Jun. 29, 2013
Contingent Consideration [Member]	'	'	'	'
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]	'	'	'	'
Beginning Balance	$33.10	$20	$5.10	$20.10
Acquisition	0	0	29.1	0
Payments	-5	0	-6.1	0
Change in fair value included in earnings	3.6	13.6	3.6	13.6
Currency translation	0.3	0.1	0.3	0
Ending Balance	32	33.7	32	33.7
Auction Rate Securities [Member]	'	'	'	'
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]	'	'	'	'
Net Gain Included In Earnings	$1.40	'	'	'

Fair_Value_Measurements_Deriva

Fair Value Measurements, Derivative Instruments (Details) (USD $)

Jun. 28, 2014

Dec. 31, 2013

Jun. 28, 2014

Dec. 31, 2013

Jun. 28, 2014

Jun. 29, 2013

Jun. 28, 2014

Jun. 29, 2013

Jun. 28, 2014

Jun. 29, 2013

Jun. 28, 2014

Jun. 29, 2013

Jun. 28, 2014

Dec. 31, 2013

Jun. 28, 2014

Dec. 31, 2013

In Millions, unless otherwise specified

Interest Rate Swaps [Member]

Foreign Currency Exchange Contracts [Member]

Other Expense [Member]

Derivatives Designated as Hedging Instruments

Cost of Revenues [Member]

Other Expense [Member]

Derivatives Not Designated as Fair Value Hedges

Derivatives Designated as Fair Value Hedges [Member]

Other Long-term Liabilities [Member]

Derivatives Not Designated as Fair Value Hedges

Other Current Assets [Member]

Accrued Expense [Member]

Derivatives Fair Value [Line Items]

Notional Amount Of Derivatives

$3,500

$2,030

Fair Value - Assets

Derivative Asset, Fair Value

3.9

3.8

Fair Value - Liabilities

Derivative Liability, Fair Value

1.4

5.2

5.4

1.3

Derivative Instruments, Gain (Loss) [Line Items]

Gain (Loss) Recognized

2.1

3.4

-0.5

4.2

0.5

-0.5

-1.9

0.2

14.8

Ineffective Portion of Gain (Loss) Recognized

$1.10

$1.80

Fair_Value_of_Other_Instrument

Fair Value of Other Instruments (Details) (USD $)	Jun. 28, 2014	Dec. 31, 2013
In Millions, unless otherwise specified	Jun. 28, 2014	Dec. 31, 2013
Other Financial Instruments [Abstract]	'	'
Notes Receivable - Carrying Value	$6.80	$7.60
Notes Receivable - Fair Value	6.8	7.6
Carrying Value and Fair Value of Other Financial Instruments [Line Items]	'	'
Debt Obligations - Carrying Value	15,577.10	10,487.30
Debt Obligations - Fair Value	15,937.10	10,596.70
Senior Notes [Member]	'	'
Carrying Value and Fair Value of Other Financial Instruments [Line Items]	'	'
Debt Obligations - Carrying Value	12,126.80	10,195.40
Debt Obligations - Fair Value	12,486.80	10,304.80
Term Loan	'	'
Carrying Value and Fair Value of Other Financial Instruments [Line Items]	'	'
Debt Obligations - Carrying Value	2,850	0
Debt Obligations - Fair Value	2,850	0
U.S. Commercial Paper Program [Member]	'	'
Carrying Value and Fair Value of Other Financial Instruments [Line Items]	'	'
Debt Obligations - Carrying Value	556.2	250
Debt Obligations - Fair Value	556.2	250
Other Debt [Member]	'	'
Carrying Value and Fair Value of Other Financial Instruments [Line Items]	'	'
Debt Obligations - Carrying Value	44.1	41.9
Debt Obligations - Fair Value	$44.10	$41.90

Supplemental_Cash_Flow_Informa2

Supplemental Cash Flow Information (Details) (USD $)	6 Months Ended
In Millions, unless otherwise specified	Jun. 28, 2014	Jun. 29, 2013
Non-cash Activities [Abstract]	'	'
Fair value of assets of acquired businesses	$19,649.10	'
Cash paid for acquired businesses	-13,529	'
Liabilities assumed of acquired businesses	6,120.10	'
Fair value of available-for-sale investments contributed to defined benefit plans	'	27.1
Declared but unpaid dividends	61.4	55.2
Issuance of stock upon vesting of restricted stock units	$76.80	$53.50

Restructuring_and_Other_Costs_2

Restructuring and Other Costs (Income), Net (Details) (USD $)	3 Months Ended		6 Months Ended
In Millions, unless otherwise specified	Jun. 28, 2014	Jun. 29, 2013	Jun. 28, 2014	Jun. 29, 2013	Aug. 01, 2014
Restructuring And Other Costs, Net Disclosure	'	'	'	'	'
Restructuring and Related Cost, Percentage of Total Workforce Eliminated	'	'	1.00%	'	'
Identified Future Restructuring Costs	'	'	'	'	$70
Restructuring Reserve [Line Items]	'	'	'	'	'
Cost of Revenues	156.1	'	324.6	'	'
Selling, General and Administrative Expenses	14.9	'	97.7	'	'
Restructuring and Other Costs (Income), Net	60.9	21.5	-521.3	43	'
Total Restructuring and Other Costs (Income), Net	231.9	'	-99	'	'
Restructuring and Related Costs, Non-Cash Costs (Income), Net	'	'	1.9	'	'
Gain (Loss) Related To Pre-acquisition Litigation-related Matter	'	'	-10.9	'	'
Gain (Loss) on Divestiture of Businesses	'	'	761.8	0	'
Monetized Equity Awards [Member]	'	'	'	'	'
Restructuring Reserve [Line Items]	'	'	'	'	'
Restructuring and Related Costs, Non-Cash Costs (Income), Net	'	'	19.6	'	'
Life Sciences Solutions [Member]	'	'	'	'	'
Restructuring Reserve [Line Items]	'	'	'	'	'
Cost of Revenues	155.8	'	324.8	'	'
Selling, General and Administrative Expenses	12.3	'	95.1	'	'
Restructuring and Other Costs (Income), Net	47.4	'	-540.7	'	'
Total Restructuring and Other Costs (Income), Net	215.5	'	-120.8	'	'
Restructuring and Related Costs, Cash Costs	39.7	'	208.5	'	'
Gain (Loss) Related To Pre-acquisition Litigation-related Matter	-10.9	'	-10.9	'	'
Gain (Loss) on Divestiture of Businesses	3.2	'	760.4	'	'
Life Sciences Solutions [Member] \| Severance [Member]	'	'	'	'	'
Restructuring Reserve [Line Items]	'	'	'	'	'
Restructuring and Related Costs, Cash Costs	34.2	'	'	'	'
Life Sciences Solutions [Member] \| Abandonment of Excess Facilities [Member]	'	'	'	'	'
Restructuring Reserve [Line Items]	'	'	'	'	'
Restructuring and Related Costs, Cash Costs	0.8	'	'	'	'
Life Sciences Solutions [Member] \| Other Restructuring [Member]	'	'	'	'	'
Restructuring Reserve [Line Items]	'	'	'	'	'
Restructuring and Related Costs, Cash Costs	4.7	'	'	'	'
Life Sciences Solutions [Member] \| Monetized Equity Awards [Member]	'	'	'	'	'
Restructuring Reserve [Line Items]	'	'	'	'	'
Restructuring and Related Costs, Cash Costs	'	'	91.7	'	'
Life Sciences Solutions [Member] \| Transaction Costs Related to Acquisition [Member]	'	'	'	'	'
Restructuring Reserve [Line Items]	'	'	'	'	'
Selling, General and Administrative Expenses	'	'	77.9	'	'
Life Sciences Solutions [Member] \| Costs to Conform Accounting Policies [Member]	'	'	'	'	'
Restructuring Reserve [Line Items]	'	'	'	'	'
Cost of Revenues	'	'	21.4	'	'
Selling, General and Administrative Expenses	'	'	16.2	'	'
Life Sciences Solutions [Member] \| Charges for Sales of Inventories Revalued at Acquisition [Member]	'	'	'	'	'
Restructuring Reserve [Line Items]	'	'	'	'	'
Cost of Revenues	'	'	302.3	'	'
Analytical Instruments [Member]	'	'	'	'	'
Restructuring Reserve [Line Items]	'	'	'	'	'
Cost of Revenues	0	'	-0.8	'	'
Selling, General and Administrative Expenses	1.1	'	1.1	'	'
Restructuring and Other Costs (Income), Net	3.1	'	4.3	'	'
Total Restructuring and Other Costs (Income), Net	4.2	'	4.6	'	'
Restructuring and Related Costs, Cash Costs	3	'	'	'	'
Analytical Instruments [Member] \| Severance [Member]	'	'	'	'	'
Restructuring Reserve [Line Items]	'	'	'	'	'
Restructuring and Related Costs, Cash Costs	1.4	'	'	'	'
Analytical Instruments [Member] \| Abandonment of Excess Facilities [Member]	'	'	'	'	'
Restructuring Reserve [Line Items]	'	'	'	'	'
Restructuring and Related Costs, Cash Costs	0.8	'	'	'	'
Analytical Instruments [Member] \| Other Restructuring [Member]	'	'	'	'	'
Restructuring Reserve [Line Items]	'	'	'	'	'
Restructuring and Related Costs, Cash Costs	0.8	'	'	'	'
Specialty Diagnostics [Member]	'	'	'	'	'
Restructuring Reserve [Line Items]	'	'	'	'	'
Cost of Revenues	0.2	'	0.4	'	'
Selling, General and Administrative Expenses	1.5	'	1.5	'	'
Restructuring and Other Costs (Income), Net	4.9	'	7.7	'	'
Total Restructuring and Other Costs (Income), Net	6.6	'	9.6	'	'
Restructuring and Related Costs, Cash Costs	4.9	'	8.7	'	'
Restructuring and Related Costs, Non-Cash Costs (Income), Net	'	'	-1	'	'
Specialty Diagnostics [Member] \| Severance [Member]	'	'	'	'	'
Restructuring Reserve [Line Items]	'	'	'	'	'
Restructuring and Related Costs, Cash Costs	2.6	'	4.7	'	'
Laboratory Products and Services [Member]	'	'	'	'	'
Restructuring Reserve [Line Items]	'	'	'	'	'
Cost of Revenues	0.1	'	0.2	'	'
Selling, General and Administrative Expenses	0	'	'	'	'
Restructuring and Other Costs (Income), Net	4	'	5.2	'	'
Total Restructuring and Other Costs (Income), Net	4.1	'	5.4	'	'
Restructuring and Related Costs, Cash Costs	3.9	'	5	'	'
Laboratory Products and Services [Member] \| Severance [Member]	'	'	'	'	'
Restructuring Reserve [Line Items]	'	'	'	'	'
Restructuring and Related Costs, Cash Costs	2.2	'	'	'	'
Laboratory Products and Services [Member] \| Abandonment of Excess Facilities [Member]	'	'	'	'	'
Restructuring Reserve [Line Items]	'	'	'	'	'
Restructuring and Related Costs, Cash Costs	1.4	'	'	'	'
Corporate [Member]	'	'	'	'	'
Restructuring Reserve [Line Items]	'	'	'	'	'
Selling, General and Administrative Expenses	0	'	'	'	'
Restructuring and Other Costs (Income), Net	1.5	'	2.2	'	'
Total Restructuring and Other Costs (Income), Net	1.5	'	2.2	'	'
Corporate [Member] \| Severance [Member]	'	'	'	'	'
Restructuring Reserve [Line Items]	'	'	'	'	'
Restructuring and Related Costs, Cash Costs	'	'	$0.90	'	'

Restructuring_Reserves_Details

Restructuring Reserves (Details) (USD $)	6 Months Ended
In Millions, unless otherwise specified	Jun. 28, 2014
Severance [Member]	'
Restructuring Reserve [Roll Forward]	'
Restructuring Reserve, Expected Final Year of Payments	'2015
Abandonment of Excess Facilities [Member]	'
Restructuring Reserve [Roll Forward]	'
Restructuring Reserve, Expected Final Year of Payments	'2020
Other Restructuring [Member]	'
Restructuring Reserve [Roll Forward]	'
Restructuring Reserve, Expected Final Year of Payments	'2014
Pre-2013 Restructuring Plans [Member]	'
Restructuring Reserve [Roll Forward]	'
Beginning balance	14.9
Costs incurred	3
Reserves reversed	-1.4
Payments	-4.3
Currency translation	-0.3
Ending balance	11.9
Pre-2013 Restructuring Plans [Member] \| Severance [Member]	'
Restructuring Reserve [Roll Forward]	'
Beginning balance	6.6
Costs incurred	1.1
Reserves reversed	-1.3
Payments	-2.4
Currency translation	-0.3
Ending balance	3.7
Pre-2013 Restructuring Plans [Member] \| Abandonment of Excess Facilities [Member]	'
Restructuring Reserve [Roll Forward]	'
Beginning balance	8
Costs incurred	1.9
Reserves reversed	0
Payments	-1.8
Currency translation	0
Ending balance	8.1
Pre-2013 Restructuring Plans [Member] \| Other Restructuring [Member]	'
Restructuring Reserve [Roll Forward]	'
Beginning balance	0.3
Costs incurred	0
Reserves reversed	-0.1
Payments	-0.1
Currency translation	0
Ending balance	0.1
2013 Restructuring Plans [Member]	'
Restructuring Reserve [Roll Forward]	'
Beginning balance	25.6
Costs incurred	11.9
Reserves reversed	-2.7
Payments	-20
Currency translation	0.3
Ending balance	15.1
2013 Restructuring Plans [Member] \| Severance [Member]	'
Restructuring Reserve [Roll Forward]	'
Beginning balance	22
Costs incurred	4.9
Reserves reversed	-2.4
Payments	-13.6
Currency translation	0.1
Ending balance	11
2013 Restructuring Plans [Member] \| Abandonment of Excess Facilities [Member]	'
Restructuring Reserve [Roll Forward]	'
Beginning balance	1.4
Costs incurred	1.7
Reserves reversed	-0.2
Payments	-1.7
Currency translation	0.2
Ending balance	1.4
2013 Restructuring Plans [Member] \| Other Restructuring [Member]	'
Restructuring Reserve [Roll Forward]	'
Beginning balance	2.2
Costs incurred	5.3
Reserves reversed	-0.1
Payments	-4.7
Currency translation	0
Ending balance	2.7
2014 Restructuring Plans [Member]	'
Restructuring Reserve [Roll Forward]	'
Costs incurred	197.3
Payments	-163.5
Currency translation	0.1
Ending balance	33.9
2014 Restructuring Plans [Member] \| Severance [Member]	'
Restructuring Reserve [Roll Forward]	'
Costs incurred	111.9
Payments	-82.6
Currency translation	0.1
Ending balance	29.4
2014 Restructuring Plans [Member] \| Abandonment of Excess Facilities [Member]	'
Restructuring Reserve [Roll Forward]	'
Costs incurred	1.2
Payments	-0.4
Currency translation	0
Ending balance	0.8
2014 Restructuring Plans [Member] \| Other Restructuring [Member]	'
Restructuring Reserve [Roll Forward]	'
Costs incurred	84.2
Payments	-80.5
Currency translation	0
Ending balance	3.7

Discontinued_Operations_Detail

Discontinued Operations (Details) (USD $)	6 Months Ended
In Millions, unless otherwise specified	Jun. 29, 2013
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]	'
Discontinued Operation, Amount of Adjustment to Prior Period Gain (Loss) on Disposal, Net of Tax	($4.20)

Additional_Accounting_Policy_a

Additional Accounting Policy and Balance Sheet Disclosures (Details) (USD $)	Jun. 28, 2014	Dec. 31, 2013
In Billions, unless otherwise specified	Jun. 28, 2014	Dec. 31, 2013
Derivative Instruments and Hedging Activities Disclosures [Line Items]	'	'
Notional Amount Of Derivatives	$3.50	$2.03

Acquisitionrelated_Intangible_1

Acquisition-related Intangible Assets, Future Amortization Expense (Details) (USD $)	Jun. 28, 2014	Dec. 31, 2013
In Millions, unless otherwise specified	Jun. 28, 2014	Dec. 31, 2013
Definite-Lived Intangible Assets, Future Amortization Expense [Abstract]	'	'
Definite-Lived Intangible Assets, Net	$13,777.40	$5,733.60

Goodwill_Details

Goodwill (Details) (USD $)	Jun. 28, 2014	Dec. 31, 2013
In Millions, unless otherwise specified	Jun. 28, 2014	Dec. 31, 2013
Goodwill [Roll Forward]	'	'
Beginning balance	$19,439.30	$12,503.30
Ending balance	$19,439.30	$12,503.30

Geographical_Information_Detai

Geographical Information (Details) (USD $)	3 Months Ended		6 Months Ended
In Millions, unless otherwise specified	Jun. 28, 2014	Jun. 29, 2013	Jun. 28, 2014	Jun. 29, 2013
Revenues from External Customers and Long-Lived Assets [Line Items]	'	'	'	'
Revenues	$4,321.90	$3,240.10	$8,225.40	$6,431.60

Pensions_Benefit_Obligations_D

Pensions Benefit Obligations (Details) (Pension Plans, Defined Benefit [Member], USD $)	3 Months Ended		6 Months Ended
In Millions, unless otherwise specified	Jun. 28, 2014	Jun. 29, 2013	Jun. 28, 2014	Jun. 29, 2013
Pension Plans, Defined Benefit [Member]	'	'	'	'
Change in Projected Benefit Obligation [Roll Forward]	'	'	'	'
Service costs	$5	$5.80	$9.60	$9.40
Interest costs	$23.50	$11.90	$43.60	$23.90

Pensions_Plan_Assets_Excluding

Pensions Plan Assets Excluding FV Disclosures (Details) (USD $)	6 Months Ended
In Millions, unless otherwise specified	Jun. 28, 2014	Jun. 29, 2013
Change in Fair Value of Plan Assets [Roll Forward]	'	'
Employer contribution	$25.70	$22.60
Fair value of available-for-sale investments contributed to defined benefit plans	'	$27.10

Income_Taxes_Components_Detail

Income Taxes Components (Details) (USD $)	3 Months Ended		6 Months Ended
In Millions, unless otherwise specified	Jun. 28, 2014	Jun. 29, 2013	Jun. 28, 2014	Jun. 29, 2013
Components of Income From Continuing Operations Before Income Taxes [Abstract]	'	'	'	'
Income from Continuing Operations Before Income Taxes	$236.50	$280	$1,010.90	$622.90
Components of Income Tax Expense (Benefit), Continuing Operations [Abstract]	'	'	'	'
Provision for Income Taxes	-42	2.4	189.3	4.5
Excess income tax benefits from stock-based compensation plans recognized in equity	'	'	$55.50	$28.40

Unaudited_Quarterly_Informatio

Unaudited Quarterly Information (Details) (USD $)	3 Months Ended		6 Months Ended
In Millions, except Per Share data, unless otherwise specified	Jun. 28, 2014	Jun. 29, 2013	Jun. 28, 2014	Jun. 29, 2013
Unaudited Quarterly Information [Abstract]	'	'	'	'
Revenues	$4,321.90	$3,240.10	$8,225.40	$6,431.60
Income from Continuing Operations	278.5	277.6	821.6	618.4
Net income	278.5	277.4	821.6	613.6
Earnings per Share from Continuing Operations [Abstract]	'	'	'	'
Basic (in dollars per share)	$0.70	$0.77	$2.07	$1.72
Diluted (in dollars per share)	$0.69	$0.76	$2.05	$1.71
Earnings per Share	'	'	'	'
Basic (in dollars per share)	$0.70	$0.77	$2.07	$1.71
Diluted (in dollars per share)	$0.69	$0.76	$2.05	$1.69
Cash Dividends Declared per Common Share (in dollars per share)	$0.15	$0.15	$0.30	$0.30
Total Restructuring and Other Costs (Income), Net	$231.90	'	($99)	'

Schedule_II_Valuation_and_Qual

Schedule II - Valuation and Qualifying Accounts (Details) (USD $)	6 Months Ended
In Millions, unless otherwise specified	Jun. 28, 2014
Valuation and Qualifying Accounts Disclosure [Line Items]	'
Restructuring and Related Costs, Non-Cash Costs	$1.90